Multi-specific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function replacement activity and pharmaceutical formulations containing said molecules as active ingredient

By introducing amino acid substitution and electrostatic repulsion modification between the heavy and light chains of the antibody, an efficient multispecific antibody was developed, which solved the problem of insufficient functional substitution activity of FVIII cofactors in patients with hemophilia A, and achieved a lower level of More effective replacement of coagulation function at concentrations reduces the frequency of treatment.

CN118994408APending Publication Date: 2024-11-22CHUGAI PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410898618.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-09-29
Filing Date
2018-09-27
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing coagulation factor VIII (FVIII) preparations have antibody responses in patients with hemophilia A, resulting in reduced efficacy and requires frequent injections. The existing bispecific antibodies such as ACE910 have insufficient functional substitution activity and cannot Completely replaces the function of FVIII and does not work well at low concentrations.

Method used

Develop multispecific antigen-binding molecules with high functional substitution activity of FVIII cofactors, and improve the association efficiency of antibodies by introducing amino acid substitution between the heavy and light chains of the antibody, especially electrostatic repulsion modification in the CH1 and CL regions. , forming efficient bispecific antibodies that can exhibit functional replacement activity of FVIII cofactors at low concentrations.

Benefits of technology

It significantly improves the functional replacement activity of FVIII cofactors, reduces the bleeding rate, and reduces the frequency of drug use. It is suitable for patients with hemophilia produced by anti-ACE910 unique antibody, and provides a more effective treatment plan for hemophilia A.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

A bispecific antibody has been successfully found, the FIX activation inhibitory activity of which is not increased and the FVIII cofactor function replacement activity of which is increased.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese application number 201880060090.X, filed on September 27, 2018, and entitled “Multi-specific antigen binding molecules with cofactor function replacement activity for coagulation factor VIII (FVIII) and pharmaceutical preparations containing the molecules as active ingredients”. Technical Field

[0002] The present invention relates to multispecific antigen-binding molecules having the activity of replacing the cofactor function of coagulation factor VIII (FVIII) and pharmaceutical preparations thereof. The present invention also relates to antigen-binding molecules in which the association between heavy chains and light chains is regulated, methods for producing antigen-binding molecules in which the association between heavy chains and light chains is regulated, and methods for regulating the association between heavy chains and light chains of antigen-binding molecules. Background Art

[0003] Hemophilia A is a bleeding abnormality caused by the hereditary reduction or lack of coagulation factor VIII (FVIII) function. For bleeding, FVIII preparations are generally administered to hemophilia A patients (administered as needed). In recent years, FVIII preparations have also been administered prophylactically to prevent bleeding episodes (preventive administration; non-patent literature 1 and 2). The half-life of FVIII preparations in blood is about 12 to 16 hours. Therefore, in order to continue prevention, FVIII preparations are administered to patients three times a week (non-patent literature 3 and 4). In administration as needed, FVIII preparations are also administered additionally on a regular basis to prevent rebleeding when necessary. In addition, FVIII preparations are administered intravenously. Therefore, it is strongly desired to have a less burdened medicament than FVIII preparations.

[0004] Occasionally, anti-FVIII antibodies (inhibitors) are produced in hemophiliacs. This inhibitor counteracts the effect of FVIII preparations. For bleeding in patients (inhibitor patients) who have produced inhibitors, bypass preparations are used. Their mechanism of action is independent of FVIII function, i.e., the function of catalyzing the activation of coagulation factor X (FX) by activated coagulation factor IX (FIXa). Therefore, in some cases, bypass preparations cannot fully stop bleeding. Therefore, it is strongly desired that the medicament that is not affected by the presence of inhibitors and can functionally replace FVIII.

[0005] As a means to solve these problems, the bispecific antibodies and uses thereof for replacing the function of FVIII have been reported (patent documents 1, 2, 3 and 4). The bispecific antibodies for FIXa and FX can replace the function of FVIII by placing these two factors close to each other to show the FVIII cofactor function replacement activity (non-patent literature 5). It is reported that the FVIII cofactor function replacement activity of antibody can be improved by optimizing the affinity and orientation to FIXa and FX (non-patent literature 6). In addition, the FVIII cofactor function replacement activity of known antibodies is affected by the presence or absence of IgG isotypes, disulfide bond patterns, the amino acid sequence of hinge regions, and sugar chains in Fc regions (non-patent literature 7). It is reported that ACE910 (Emicizumab, Emicizumab) with high FVIII cofactor function replacement activity for one of these antibodies shows hemostatic effect in the monkey model of hemophilia (non-patent literature 8 and 9). In addition, in clinical trials on healthy subjects, ACE910 (Emicizumab) was demonstrated to achieve excellent pharmacokinetics (long half-life) and tolerability (Non-Patent Document 10), and in clinical trials on hemophilia A patients with or without inhibitors, the administration of ACE910 (Emicizumab) significantly reduced the bleeding rate compared to before the administration of ACE910 (Emicizumab) (Non-Patent Document 11).

[0006] As mentioned above, in clinical trials, the effect of reducing bleeding rate was observed for ACE910 (Amicizumab). However, in the in vitro thrombin generation assay using FVIII lacking plasma, the maximum amount (peak height) of thrombin generation by ACE910 (Amicizumab) was lower than the amount generated in the presence of the normal level of FVIII, and it was 100U / dL (non-patent literature 8). Therefore, it is expected to further enhance drug efficacy. In addition, considering the convenience to hemophilia A patients, it is necessary to have FVIII cofactor function alternative active bispecific antibodies, which can be further reduced by the increase of specific activity, etc., in terms of administration dosage.

[0007] Typically, in some cases, antibody drugs act as antigens to induce anti-antibody (ADA) production (non-patent literature 12). Since the continuous administration of ACE910 (Emicizumab) becomes difficult for hemophiliacs with ADA (anti-ACE910 (Emicizumab) idiotypic antibodies), it is necessary to apply to such patients with bispecific antibodies with FVIII cofactor function replacement activity.

[0008] ACE910 (Emicizumab) is a bispecific antibody optimized from multiple aspects by introducing many amino acid substitutions into the lead antibody hBS1. Lead antibody hBS1 is obtained by humanized bispecific antibody, which is obtained by animal immunization, and it recognizes FIX and / or FIXa, and FX. ACE910 (Emicizumab) has high FVIII cofactor function substitution activity (non-patent literature 6 and patent literature 4). However, in order to enhance drug efficacy and improve specific activity, it is necessary to replace the bispecific antibody of FVIII function, which has a higher maximum activity (maximum FVIII cofactor function substitution activity) than ACE910 (Emicizumab), and can show FVIII cofactor function substitution activity at a concentration lower than ACE910 (Emicizumab). However, so far, from the viewpoint of concentration and maximum activity, there is no report (patent literature 4 and 5) on bispecific antibodies with significantly high FVIII cofactor function substitution activity compared with ACE910 (Emicizumab).

[0009] Several methods have been reported previously as methods for preparing IgG type bispecific antibodies with human constant regions (IgG type antibodies with human constant regions, with binding specificity to antigen A on one arm, and with binding specificity to antigen B on the other arm). Typically, IgG type bispecific antibodies are composed of two types of H chains (i.e., H chains for antigen A and H chains for antigen B) and two types of L chains (i.e., L chains for antigen A and L chains for antigen B). When such IgG type bispecific antibodies are expressed, owing to the expression of two types of H chains and two types of L chains, as a combination of H2L2, ten types of combinations are possible. Among these, there is a type of combination with the desired binding specificity (IgG with binding specificity to antigen A on one arm, and with binding specificity to antigen B on the other arm). Therefore, in order to obtain the desired bispecific antibody, it is necessary to purify one type of target antibody from ten types of antibodies, which is extremely inefficient and difficult.

[0010] Methods for solving this problem have been reported, which involve preferentially secreting IgG having a heterologous combination of an H chain against antigen A and an H chain against antigen B by replacing amino acids in the CH3 region of the IgG H chain (Patent Documents 6, 7, 8, and 9, and Non-Patent Documents 13 and 14). Among these methods, methods using physical barriers in the form of "knobs" and "holes", and those using charge repulsion have been reported.

[0011] It has also been reported that the method for effectively obtaining the desired molecule uses a common L chain, wherein the L chain for antigen A and the L chain for antigen B are present on the same amino acid sequence (patent documents 10 and 11). However, since the use of a common L chain has the possibility of greatly reducing the affinity of the antigen, this is not necessarily the best method. Therefore, in order for bispecific antibodies to bind to two antigens with high affinity, it is preferred that only the L chain and H chain for antigen A are associated, and only the L chain and H chain for antigen B are associated. In addition, it has been reported that the method for allowing the H chain and L chain for each antigen to associate independently of the variable region is included in the constant region CH1 and CL domains, rather than replacing amino acids in the variable region (patent documents 7, 12 and 13). However, this method has many areas to be improved for effectively producing target bispecific antibodies.

[0012] [Citation List]

[0013] [Patent Document]

[0014] [Patent Document 1] WO 2005 / 035754

[0015] [Patent Document 2] WO 2005 / 035756

[0016] [Patent Document 3] WO 2006 / 109592

[0017] [Patent Document 4] WO 2012 / 067176

[0018] [Patent Document 5] WO 2017 / 110980

[0019] [Patent Document 6] WO 1996 / 027011

[0020] [Patent Document 7] WO 2006 / 106905

[0021] [Patent Document 8] WO 2009 / 089004

[0022] [Patent Document 9] WO 2010 / 129304

[0023] [Patent Document 10] WO 98 / 050431

[0024] [Patent Document 11] WO 2006 / 109592

[0025] [Patent Document 12] WO 2007 / 147901

[0026] [Patent Document 13] WO 2013 / 065708

[0027] [Non-patent literature]

[0028] [Non-patent document 1] Blood 58, 1-13 (1981)

[0029] [Non-patent document 2] Nature 312, 330-337 (1984)

[0030] [Non-patent document 3] Nature 312, 337-342 (1984)

[0031] [Non-patent document 4] Biochim. Biophys. Acta 871, 268-278 (1986)

[0032] [Non-patent document 5] Nat Med. 2012 Oct; 18(10): 1570-4.

[0033] [Non-patent document 6] PLoS One. 2013; 8(2): e57479.

[0034] [Non-patent document 7] MAbs. 2015; 7(1): 120-8.

[0035] [Non-patent document 8] J Thromb Haemost. 2014 Feb; 12(2): 206-213.

[0036] [Non-patent document 9] Blood. 2014 Nov 13; 124(20): 3165-71.

[0037] [Non-patent document 10] Blood. 2016, Vol. 127, 13

[0038] [Non-patent document 11] New Eng J Med 2016, 374; 21, 2044-2053

[0039] [Non-patent document 12] Self / Nonself Volume 1, 2010-Issue 4

[0040] [Non-patent document 13] Protein Engineering. 1996, Vol. 9: 617-621

[0041] [Non-patent document 14] Nature Biotechnology. 1998, Vol. 16: 677-681 SUMMARY OF THE INVENTION

[0043] [Problems to be Solved by the Invention]

[0044] The present invention has been achieved in view of the above circumstances. An object of the present invention is to provide a multispecific antigen-binding molecule having the activity of replacing the cofactor function of coagulation factor VIII (FVIII) and a pharmaceutical preparation containing the molecule as an active ingredient.

[0045] Furthermore, the present invention has been achieved in view of the above circumstances. Another object of the present invention is to provide an antibody in which the association between the heavy chain and the light chain is regulated, a method for producing an antibody in which the association between the heavy chain and the light chain is regulated, and a method for controlling the association between the heavy chain and the light chain of an antibody.

[0046] [Methods of solving the problem]

[0047] In order to obtain a bispecific antibody with high specific activity and maximum FVIII cofactor function replacement activity, the inventors obtained a novel light chain with a sequence different from ACE910 (Emicizumab) from a human antibody library, which has FVIII cofactor function replacement activity, and prepared a bispecific antibody in which amino acid substitutions have been introduced at multiple sites of the light chain and ACE910 (Emicizumab) heavy chain. Then, they found that the coagulation factor IX (FIX) activation inhibition activity increased with the increase of FVIII cofactor function replacement activity.

[0048] As a result of dedicated studies, the present inventors have successfully discovered a bispecific antibody whose FIX activation inhibitory activity is not increased and whose FVIII cofactor function replacing activity is increased.

[0049] Furthermore, the present inventors selected the heavy chain constant region CH1 and the light chain constant region (CL) as the heavy chain and light chain regions to be subjected to association regulation, and conducted special studies on the regulation of the association between CH1 and CL. As a result, the present inventors successfully found that by replacing specific amino acid residues present at the interface between CH1 and CL with amino acid residues that electrostatically repel each other, the undesirable association of CH1 and CL can be suppressed, and a heterologous molecule can be formed more efficiently than by using the above-mentioned modification of introducing only a knob and a hole into CH3.

[0050] The present invention is based on these findings and specifically provides the following [1] to

[25] :

[0051] [1] A multispecific antigen-binding molecule having a function of replacing the function of coagulation factor VIII, wherein the molecule comprises a first antigen-binding site that binds to coagulation factor IX and / or activated coagulation factor IX, and a second antigen-binding site that binds to coagulation factor X,

[0052] wherein the first antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0053] wherein the heavy chain variable domain (Q499) comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and

[0054] The light chain variable domain (QNK131) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 162, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 163, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 164, and

[0055] wherein the second antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0056] wherein the heavy chain variable domain (J327) comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 4, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6, and

[0057] The light chain variable domain (JNL095) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 165, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 166, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 167;

[0058] wherein in at least one HVR, one or more amino acid residues are substituted, deleted or inserted by other amino acids;

[0059] [2] The multispecific antigen-binding molecule of [1], wherein:

[0060] In the heavy chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 97, 98, 100, 100a, 100b and 100e according to Kabat numbering is substituted by another amino acid or is deleted,

[0061] In the light chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 53, 55, 92, 93, 95 and 96 according to Kabat numbering is substituted or inserted by another amino acid,

[0062] In the heavy chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 51, 56, 57, 59, 61, 62, 65 and 102 according to Kabat numbering is substituted by another amino acid,

[0063] In the light chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the group consisting of amino acid residues at positions 24, 26, 27, 29, 30, 31, 32, 50, 92, 94, 95, 95a and 96 according to Kabat numbering is substituted or deleted;

[0064] [3] The multispecific antigen-binding molecule of [1] or [2], wherein:

[0065] in the heavy chain variable domain of the first antigen-binding site, the amino acid residue at position 31 is histidine, the amino acid residue at position 34 is alanine, the amino acid residue at position 97 is aspartic acid, the amino acid residue at position 98 is serine, the amino acid residue at position 100 is aspartic acid or glutamic acid, the amino acid residue at position 100a is aspartic acid or is missing, the amino acid residue at position 100b is alanine or histidine, or the amino acid residue at position 100e is histidine or isoleucine, the positions being numbered according to Kabat;

[0066] in the light chain variable domain of the first antigen-binding site, the amino acid residue at position 26 is threonine, the amino acid residue at position 27 is arginine, the amino acid residue at position 30 is arginine, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is aspartic acid or glutamic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 92 is arginine, the amino acid residue at position 93 is serine or aspartic acid, the amino acid residue at position 95 is proline, or the amino acid residue at position 96 is glycine, the positions being numbered according to Kabat;

[0067] in the heavy chain variable domain of the second antigen-binding site, the amino acid residue at position 31 is asparagine, glutamine or histidine, the amino acid residue at position 51 is serine, the amino acid residue at position 56 is threonine or arginine, the amino acid residue at position 57 is valine, the amino acid residue at position 59 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is lysine, the amino acid residue at position 65 is asparagine or glutamine, or the amino acid residue at position 102 is valine, the positions being numbered according to Kabat; and

[0068] in the light chain variable domain of the second antigen-binding site, the amino acid residue at position 24 is threonine, the amino acid residue at position 26 is glutamic acid, the amino acid residue at position 27 is glutamine, the amino acid residue at position 29 is serine, the amino acid residue at position 30 is glutamine, serine or glutamic acid, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is glutamine or glutamic acid, the amino acid residue at position 50 is glutamine, the amino acid residue at position 92 is alanine, the amino acid residue at position 94 is aspartic acid, the amino acid residue at position 95 is aspartic acid or alanine, the amino acid residue at position 95a is tyrosine or is missing, or the amino acid residue at position 96 is threonine, the positions being numbered according to Kabat;

[0069] [4] The multispecific antigen-binding molecule of any one of [1] to [3], wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises:

[0070] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 168, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 169, and HVR-H3 (QH01) comprising the amino acid sequence of SEQ ID NO: 170;

[0071] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 171, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 172, and HVR-H3 (QH02) comprising the amino acid sequence of SEQ ID NO: 173;

[0072] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 174, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 175, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 176 (QH03);

[0073] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 177, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 178, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 179 (QH04);

[0074] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 180, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 181, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 182 (QH06); or

[0075] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 183, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 184, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 185 (QH07); and

[0076] The light chain variable domain comprises:

[0077] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 186, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 187, and HVR-L3 (QL21) comprising the amino acid sequence of SEQ ID NO: 188;

[0078] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 189, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 190, and HVR-L3 (QL22) comprising the amino acid sequence of SEQ ID NO: 191;

[0079] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 192, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 193, and HVR-L3 (QL23) comprising the amino acid sequence of SEQ ID NO: 194;

[0080] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 195, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 196, and HVR-L3 (QL24) comprising the amino acid sequence of SEQ ID NO: 197;

[0081] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 198, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 199, and HVR-L3 (QL25) comprising the amino acid sequence of SEQ ID NO: 200;

[0082] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO:201, HVR-L2 comprising the amino acid sequence of SEQ ID NO:202, and HVR-L3 (QL26) comprising the amino acid sequence of SEQ ID NO:203;

[0083] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO:204, HVR-L2 comprising the amino acid sequence of SEQ ID NO:205, and HVR-L3 (QL28) comprising the amino acid sequence of SEQ ID NO:206;

[0084] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO:207, HVR-L2 comprising the amino acid sequence of SEQ ID NO:208, and HVR-L3 (QL29) comprising the amino acid sequence of SEQ ID NO:209;

[0085] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO:210, HVR-L2 comprising the amino acid sequence of SEQ ID NO:211, and HVR-L3 (QL30) comprising the amino acid sequence of SEQ ID NO:212;

[0086] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO:213, HVR-L2 comprising the amino acid sequence of SEQ ID NO:214, and HVR-L3 (QL31) comprising the amino acid sequence of SEQ ID NO:215;

[0087] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO:216, HVR-L2 comprising the amino acid sequence of SEQ ID NO:217, and HVR-L3 (QL32) comprising the amino acid sequence of SEQ ID NO:218; or

[0088] 12) HVR-L1 comprising the amino acid sequence of SEQ ID NO:219, HVR-L2 comprising the amino acid sequence of SEQ ID NO:220, and HVR-L3 (QL33) comprising the amino acid sequence of SEQ ID NO:221, and

[0089] Wherein the second antigen binding site comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises:

[0090] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 222, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 223, and HVR-H3 (JH01) comprising the amino acid sequence of SEQ ID NO: 224;

[0091] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 225, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 226, and HVR-H3 (JH02) comprising the amino acid sequence of SEQ ID NO: 227;

[0092] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 228, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 229, and HVR-H3 (JH03) comprising the amino acid sequence of SEQ ID NO: 230;

[0093] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO:231, HVR-H2 comprising the amino acid sequence of SEQ ID NO:232, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:233 (JH04);

[0094] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 234, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 235, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 236 (JH05);

[0095] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 237, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 238, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 239 (JH06);

[0096] 7) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 240, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 241, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 242 (JH07);

[0097] 8) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 243, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 244, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 245 (JH08);

[0098] 9) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 246, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 247, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 248 (JH09);

[0099] 10) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 249, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 250, and HVR-H3 (JH10) comprising the amino acid sequence of SEQ ID NO: 251; or

[0100] 11) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 252, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 253, and HVR-H3 (JH11) comprising the amino acid sequence of SEQ ID NO: 254, and

[0101] The light chain variable domain comprises:

[0102] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 255, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 256, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 257 (JL01);

[0103] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 258, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 259, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 260 (JL02);

[0104] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 261, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 262, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 263 (JL03);

[0105] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 264, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 265, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 266 (JL04);

[0106] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 267, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 268, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 269 (JL05);

[0107] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 270, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 271, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 272 (JL06);

[0108] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 273, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 274, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 275 (JL07);

[0109] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 276, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 277, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 278 (JL08);

[0110] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 279, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 280, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 281 (JL09);

[0111] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 282, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 283, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 284 (JL10); or

[0112] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 285, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 286, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 287 (JL11);

[0113] [5] The multispecific antigen-binding molecule of [1], wherein the first antigen-binding site comprises the heavy chain variable domain of SEQ ID NO: 45 (Q499) and the light chain variable domain of SEQ ID NO: 13 (QNK131), and the second antigen-binding site comprises the heavy chain variable domain of SEQ ID NO: 46 (J327) and the light chain variable domain of SEQ ID NO: 31 (JNL095),

[0114] wherein in at least one heavy chain variable domain or light chain variable domain, one or more amino acid residues are substituted, deleted or inserted by other amino acids;

[0115] [6] The multispecific antigen-binding molecule of [5], wherein:

[0116] In the heavy chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 39, 97, 98, 100, 100a, 100b and 100e according to Kabat numbering is substituted by another amino acid or is deleted,

[0117] In the light chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 38, 45, 53, 55, 60, 70, 76, 79, 80, 83, 85, 92, 93, 95 and 96 according to Kabat numbering is substituted or inserted by another amino acid,

[0118] In the heavy chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the group consisting of the amino acid residues at positions 28, 31, 39, 51, 56, 57, 59, 61, 62, 65, 67, 73, 82b and 102 according to Kabat numbering is substituted by another amino acid, and

[0119] In the light chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 3, 8, 15, 24, 26, 27, 29, 30, 31, 32, 38, 48, 49, 50, 79, 92, 94, 95, 95a and 96 according to Kabat numbering is substituted by another amino acid or is deleted;

[0120] [7] The multispecific antigen-binding molecule of [5] or [6], wherein:

[0121] In the heavy chain variable domain of the first antigen-binding site, the amino acid residue at position 31 is histidine, the amino acid residue at position 34 is alanine, the amino acid residue at position 39 is glutamic acid, the amino acid residue at position 97 is aspartic acid, the amino acid residue at position 98 is serine, the amino acid residue at position 100 is aspartic acid or glutamic acid, the amino acid residue at position 100a is aspartic acid or is missing, the amino acid residue at position 100b is alanine or histidine, or the amino acid residue at position 100e is histidine or isoleucine, the positions being numbered according to Kabat,

[0122] In the light chain variable domain of the first antigen-binding site, the amino acid residue at position 26 is threonine, the amino acid residue at position 27 is arginine, the amino acid residue at position 30 is arginine, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is aspartic acid or glutamic acid, the amino acid residue at position 38 is lysine, the amino acid residue at position 45 is glutamic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 60 is aspartic acid, and the amino acid residue at position the amino acid residue at position 70 is aspartic acid, the amino acid residue at position 76 is asparagine, the amino acid residue at position 79 is glutamic acid, the amino acid residue at position 80 is proline or alanine, the amino acid residue at position 83 is methionine or alanine, the amino acid residue at position 85 is threonine, the amino acid residue at position 92 is arginine, the amino acid residue at position 93 is serine or aspartic acid, the amino acid residue at position 95 is proline, or the amino acid residue at position 96 is glycine, the positions being numbered according to Kabat,

[0123] in the heavy chain variable domain of the second antigen-binding site, the amino acid residue at position 28 is glutamic acid, the amino acid residue at position 31 is asparagine, glutamine or histidine, the amino acid residue at position 39 is lysine, the amino acid residue at position 51 is serine, the amino acid residue at position 56 is threonine or arginine, the amino acid residue at position 57 is valine, the amino acid residue at position 59 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is lysine, the amino acid residue at position 65 is asparagine or glutamine, the amino acid residue at position 67 is leucine, the amino acid residue at position 73 is isoleucine, the amino acid residue at position 82b is glutamic acid, or the amino acid residue at position 102 is valine, the positions being numbered according to Kabat, and

[0124] In the light chain variable domain of the second antigen-binding site, the amino acid residue at position 3 is glutamic acid, the amino acid residue at position 8 is proline, the amino acid residue at position 15 is leucine, the amino acid residue at position 24 is threonine, the amino acid residue at position 26 is glutamic acid, the amino acid residue at position 27 is glutamine, the amino acid residue at position 29 is serine, the amino acid residue at position 30 is glutamine, serine or glutamic acid, the amino acid residue at position 31 is arginine, and the amino acid residue at position 32 is glutamine or glutamic acid, the amino acid residue at position 38 is glutamic acid, the amino acid residue at position 48 is isoleucine, the amino acid residue at position 49 is tyrosine, the amino acid residue at position 50 is glutamine, the amino acid residue at position 79 is glutamic acid, the amino acid residue at position 92 is alanine, the amino acid residue at position 94 is aspartic acid, the amino acid residue at position 95 is aspartic acid or alanine, the amino acid residue at position 95a is tyrosine or is missing, or the amino acid residue at position 96 is threonine, the positions being numbered according to Kabat;

[0125] [8] The multispecific antigen-binding molecule according to any one of [1] to [7], wherein

[0126] The first antigen binding site comprises:

[0127] a heavy chain variable domain (QH) comprising the amino acid sequence of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, or SEQ ID NO:60, and a light chain variable domain (QL) comprising the amino acid sequence of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72; and

[0128] The second antigen binding site comprises:

[0129] a heavy chain variable domain (JH) comprising the amino acid sequence of SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82 or SEQ ID NO:83, and

[0130] a light chain variable domain (JL) comprising the amino acid sequence of SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93 or SEQ ID NO:94;

[0131] [9] The multispecific antigen-binding molecule of any one of [1] to [8], wherein the first antigen-binding site comprises a constant region comprising the amino acid sequence set forth in (1) or (2) below, and the second antigen-binding site comprises a constant region comprising the amino acid sequence set forth in (1) or (2) below, and the constant region is different from the constant region included in the first antigen-binding site:

[0132] (1) SEQ ID NO: 119 as the heavy chain constant region and SEQ ID NO: 100 as the light chain constant region;

[0133] (2) SEQ ID NO: 118 as the heavy chain constant region and SEQ ID NO: 102 as the light chain constant region;

[0134]

[10] The multispecific antigen-binding molecule of any one of [1] to [9], which is a multispecific antibody or a bispecific antibody;

[0135]

[11] A bispecific antibody comprising a first antibody heavy chain and a first antibody light chain that bind to coagulation factor IX and / or activated coagulation factor IX, and a second antibody heavy chain and a second antibody light chain that bind to coagulation factor X, wherein the bispecific antibody is any one of the following (a) to (v):

[0136] (a) a bispecific antibody (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 120, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 126, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149;

[0137] (b) a bispecific antibody (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149;

[0138] (c) a bispecific antibody (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 128, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0139] (d) a bispecific antibody (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 129, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0140] (e) a bispecific antibody (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 140, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 151;

[0141] (f) a bispecific antibody (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 141, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 152;

[0142] (g) a bispecific antibody (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0143] (h) a bispecific antibody (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 130, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0144] (i) a bispecific antibody (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0145] (j) a bispecific antibody (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0146] (k) a bispecific antibody (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0147] (l) a bispecific antibody (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154;

[0148] (m) a bispecific antibody (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0149] (n) a bispecific antibody (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154;

[0150] (o) a bispecific antibody (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155;

[0151] (p) a bispecific antibody (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 135, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 145, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 156;

[0152] (q) a bispecific antibody (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155;

[0153] (r) a bispecific antibody (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 146, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 157;

[0154] (s) a bispecific antibody (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 147, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 158;

[0155] (t) a bispecific antibody (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 125, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 137, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 148, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 159;

[0156] (u) a bispecific antibody that binds to the same epitope as the epitope of coagulation factor IX and / or activated coagulation factor IX and the epitope of coagulation factor X recognized by any one of the antibodies of (a) to (t);

[0157] (v) a bispecific antibody that competitively binds to an epitope of coagulation factor IX and / or activated coagulation factor IX and an epitope of coagulation factor X recognized by any one of the antibodies of (a) to (t);

[0158]

[12] An antigen-binding molecule wherein the association between the heavy chain and the light chain is regulated, wherein one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) to (c) below in the heavy chain and the light chain of the antigen-binding molecule are amino acid residues that electrostatically repel each other:

[0159] (a) the amino acid residue at position 175 according to EU numbering in the heavy chain constant region (CH1), and the amino acid residue at position 180 according to Kabat numbering in the light chain constant region (CL),

[0160] (b) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 131 according to Kabat numbering in CL,

[0161] (c) the amino acid residues at positions 147 and 175 according to EU numbering in CH1 and the amino acid residues at positions 131 and 180 according to Kabat numbering in CL;

[0162]

[13] The antigen-binding molecule of

[12] , wherein the other two or more amino acid residues forming the interface between the heavy chain variable region and the light chain variable region are amino acid residues that electrostatically repel each other;

[0163]

[14] The antigen-binding molecule of

[13] , wherein the amino acid residues that electrostatically repel each other are one or two groups of amino acid residues selected from the group consisting of the amino acid residues shown in (a) or (b) below:

[0164] (a) the amino acid residue at position 39 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 38 according to Kabat numbering in the light chain variable region,

[0165] (b) the amino acid residue at position 45 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 44 according to Kabat numbering in the light chain variable region;

[0166]

[15] The antigen-binding molecule of any one of

[12] to

[14] , wherein the amino acid residues that electrostatically repel each other are amino acid residues selected from the group consisting of (X) or (Y):

[0167] (X) Glutamic acid (E), Aspartic acid (D),

[0168] (Y) lysine (K), arginine (R), histidine (H);

[0169]

[16] The antigen-binding molecule of any one of

[12] to

[15] , which is a bispecific antibody;

[0170]

[17] A method for producing an antigen-binding molecule in which the association between heavy chains and light chains is regulated, wherein the method comprises the following steps (1) to (3):

[0171] (1) modifying the nucleic acids encoding the heavy chain constant region (CH1) and the light chain constant region (CL) so that one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) to (c) below electrostatically repel each other:

[0172] (a) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 180 according to Kabat numbering in CL,

[0173] (b) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 131 according to Kabat numbering in CL,

[0174] (c) the amino acid residues at positions 147 and 175 according to EU numbering in CH1 and the amino acid residues at positions 131 and 180 according to Kabat numbering in CL;

[0175] (2) introducing the modified nucleic acid into a host cell, and culturing the host cell to express the nucleic acid;

[0176] (3) collecting antigen-binding molecules from the host cell culture;

[0177]

[18] A method for regulating the association between heavy chains and light chains in an antigen-binding molecule, wherein the method comprises modifying a nucleic acid so that one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) to (c) below are amino acid residues that electrostatically repel each other:

[0178] (a) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 180 according to Kabat numbering in CL,

[0179] (b) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 131 according to Kabat numbering in CL,

[0180] (c) the amino acid residues at positions 147 and 175 according to EU numbering in CH1 and the amino acid residues at positions 131 and 180 according to Kabat numbering in CL;

[0181]

[19] An isolated nucleic acid encoding the multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , the bispecific antibody of

[10] ,

[11] or

[16] , or the antigen-binding molecule of any one of

[12] to

[15] ;

[0182]

[20] A host cell comprising the nucleic acid described in

[19] ;

[0183]

[21] A method for producing a multispecific antigen-binding molecule, a multispecific antibody, a bispecific antibody or an antigen-binding molecule, wherein the method comprises culturing the host cell of

[20] to produce the multispecific antigen-binding molecule, the multispecific antibody, the bispecific antibody or the antigen-binding molecule;

[0184]

[22] A pharmaceutical preparation comprising the multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , the bispecific antibody of

[10] ,

[11] or

[16] , or the antigen-binding molecule of any one of

[12] to

[15] , and a pharmaceutically acceptable carrier;

[0185]

[23] The pharmaceutical preparation of

[22] , which is used for preventing and / or treating bleeding, a disease involving bleeding, or a disease caused by bleeding;

[0186]

[24] The pharmaceutical preparation of

[23] , wherein the bleeding, the disease involving bleeding or the disease caused by bleeding is a disease that develops and / or progresses due to a decrease in or deficiency in the activity of coagulation factor VIII and / or activated coagulation factor VIII;

[0187]

[25] The pharmaceutical preparation described in

[24] , wherein the disease that develops and / or progresses due to a decrease in or deficiency in the activity of coagulation factor VIII and / or activated coagulation factor VIII is hemophilia A, a disease in which inhibitors to coagulation factor VIII and / or activated coagulation factor VIII appear, acquired hemophilia, or von Willebrand disease.

[0188] Furthermore, the present invention relates to the following:

[0189]

[26] The multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , the bispecific antibody of

[10] ,

[11] or

[16] , or the antigen-binding molecule of any one of

[12] to

[15] , for use as a medicament;

[0190]

[27] The multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , or the bispecific antibody of

[10] or

[11] , for use in preventing and / or treating bleeding, a disease involving bleeding, or a disease caused by bleeding;

[0191]

[28] The multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , or the bispecific antibody of

[10] or

[11] , which is used to replace the cofactor function of FVIII;

[0192]

[29] Use of the multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , or the bispecific antibody of

[10] or

[11] for the preparation of a medicament for treating bleeding, a disease involving bleeding, or a disease caused by bleeding;

[0193]

[30] Use of the multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , or the bispecific antibody of

[10] or

[11] in the preparation of a medicament for replacing the cofactor function of FVIII;

[0194]

[31] A method for treating an individual having bleeding, a disease involving bleeding, or a disease caused by bleeding, wherein the method comprises administering to the individual an effective amount of the multispecific antigen-binding molecule of any one of [1] to [9], the multispecific antibody of

[10] , or the bispecific antibody of

[10] or

[11] ; and

[0195]

[32] A method for replacing the cofactor function of FVIII in an individual, wherein the method comprises the step of administering to the individual an effective amount of the multispecific antigen-binding molecule described in any one of [1] to [9], the multispecific antibody described in

[10] , or the bispecific antibody described in

[10] or

[11] for replacing the cofactor function of FVIII.

[0196] Furthermore, the present invention relates to the following:

[0197]

[33] The method for producing an antigen-binding molecule of

[17] , comprising, in step (1), a step of modifying the nucleic acid so that the amino acid residues that electrostatically repel each other are amino acid residues selected from the group consisting of any one of the following (X) or (Y):

[0198] (X) glutamic acid (E) and aspartic acid (D); and

[0199] (Y) lysine (K), arginine (R), and histidine (H);

[0200]

[34] The method for producing an antigen-binding molecule of

[17] or

[33] , further comprising, in step (1), a step of modifying the nucleic acid so that two or more amino acid residues forming an interface between the heavy chain variable region and the light chain variable region are amino acid residues that electrostatically repel each other;

[0201]

[35]

[34] The method for producing an antigen-binding molecule, wherein the amino acid residues that electrostatically repel each other are any one of the amino acid residues selected from the group consisting of the amino acid residues shown in (a) or (b) below:

[0202] (a) the amino acid residue at position 39 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 38 according to Kabat numbering in the light chain variable region; and

[0203] (b) the amino acid residue at position 45 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 44 according to Kabat numbering in the light chain variable region;

[0204]

[36] The method for producing an antigen-binding molecule of

[34] or

[35] , wherein the amino acid residues that electrostatically repel each other are amino acid residues selected from the group consisting of (X) or (Y):

[0205] (X) glutamic acid (E) and aspartic acid (D); and

[0206] (Y) lysine (K), arginine (R), and histidine (H);

[0207]

[37]

[18] , wherein the amino acid residues that electrostatically repel each other are selected from the group consisting of the following (X) or (Y):

[0208] (X) glutamic acid (E) and aspartic acid (D); and

[0209] (Y) lysine (K), arginine (R), and histidine (H);

[0210]

[38] The method of

[18] or

[37] , wherein the other two or more amino acid residues forming an interface between the heavy chain variable region and the light chain variable region are amino acid residues that electrostatically repel each other;

[0211]

[39] The method of

[38] , wherein the amino acid residues that electrostatically repel each other are any one of the amino acid residues selected from the group consisting of the amino acid residues shown in (a) or (b) below:

[0212] (a) the amino acid residue at position 39 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 38 according to Kabat numbering in the light chain variable region; and

[0213] (b) the amino acid residue at position 45 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 44 according to Kabat numbering in the light chain variable region; and

[0214]

[40] The method of

[38] or

[39] , wherein the amino acid residues that electrostatically repel each other are amino acid residues selected from the group consisting of (X) or (Y):

[0215] (X) glutamic acid (E) and aspartic acid (D); and

[0216] (Y) Lysine (K), Arginine (R), and Histidine (H).

[0217] Furthermore, the present invention relates to the following:

[0218]

[41] The multispecific antigen-binding molecule of any one of [1] to [7], which is any one of the following (a) to (v):

[0219] (a) a multispecific antigen-binding molecule (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:61, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:84;

[0220] (b) a multispecific antigen-binding molecule (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:84;

[0221] (c) a multispecific antigen-binding molecule (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:63, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0222] (d) a multispecific antigen-binding molecule (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:64, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0223] (e) a multispecific antigen-binding molecule (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:75, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:86;

[0224] (f) a multispecific antigen-binding molecule (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 87;

[0225] (g) a multispecific antigen-binding molecule (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0226] (h) a multispecific antigen-binding molecule (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:65, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0227] (i) a multispecific antigen-binding molecule (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0228] (j) a multispecific antigen-binding molecule (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0229] (k) a multispecific antigen-binding molecule (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0230] (l) a multispecific antigen-binding molecule (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:89;

[0231] (m) a multispecific antigen-binding molecule (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0232] (n) a multispecific antigen-binding molecule (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:89;

[0233] (o) a multispecific antigen-binding molecule (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:90;

[0234] (p) a multispecific antigen-binding molecule (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:70, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:80, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:91;

[0235] (q) a multispecific antigen-binding molecule (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:90;

[0236] (r) a multispecific antigen-binding molecule (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:81, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:92;

[0237] (s) a multispecific antigen-binding molecule (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:82, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:93;

[0238] (t) a multispecific antigen-binding molecule (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 105, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 72, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 83, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 94;

[0239] (u) a multispecific antigen-binding molecule that binds to the same epitope as the epitope of coagulation factor IX and / or activated coagulation factor IX and the epitope of coagulation factor X recognized by any one of the antibodies in (a) to (t); and

[0240] (v) a multispecific antigen-binding molecule that competitively binds to an epitope of coagulation factor IX and / or activated coagulation factor IX and an epitope of coagulation factor X recognized by any one of the antibodies in (a) to (t); and

[0241]

[42] A bispecific antibody comprising a first antibody heavy chain variable domain and a first antibody light chain variable domain that bind to coagulation factor IX and / or activated coagulation factor IX, and a second antibody heavy chain variable domain and a second antibody light chain variable domain that bind to coagulation factor X, wherein the bispecific antibody is any one of the following (a) to (v):

[0242] (a) a bispecific antibody (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 56, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 61, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 84;

[0243] (b) a bispecific antibody (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 84;

[0244] (c) a bispecific antibody (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 63, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0245] (d) a bispecific antibody (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0246] (e) a bispecific antibody (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 75, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 86;

[0247] (f) a bispecific antibody (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 87;

[0248] (g) a bispecific antibody (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0249] (h) a bispecific antibody (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 65, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0250] (i) a bispecific antibody (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0251] (j) a bispecific antibody (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0252] (k) a bispecific antibody (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0253] (l) a bispecific antibody (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 89;

[0254] (m) a bispecific antibody (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0255] (n) a bispecific antibody (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 89;

[0256] (o) a bispecific antibody (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 90;

[0257] (p) a bispecific antibody (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 91;

[0258] (q) a bispecific antibody (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 90;

[0259] (r) a bispecific antibody (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 81, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 92;

[0260] (s) a bispecific antibody (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 82, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 93;

[0261] (t) a bispecific antibody (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 105, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 72, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 83, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 94;

[0262] (u) a bispecific antibody that binds to the same epitope as the epitope of coagulation factor IX and / or activated coagulation factor IX and the epitope of coagulation factor X recognized by any one of the antibodies in (a) to (t); and

[0263] (v) A bispecific antibody that competitively binds to an epitope of coagulation factor IX and / or activated coagulation factor IX and an epitope of coagulation factor X recognized by any one of the antibodies of (a) to (t). BRIEF DESCRIPTION OF THE DRAWINGS

[0265] Figure 1 The reactivity of anti-ACE910 (emicizumab) idiotype antibody to the bispecific antibody with a novel L chain is shown.

[0266] Figure 2 This indicates that the inhibitory activity of FIX activation may affect FX activation.

[0267] Figure 3 Shown is a graph of FIX activation inhibition activity plotted against FVIII cofactor function replacement activity resulting from novel L chain modifications and H chain modifications.

[0268] Figure 4-1 The concentration dependence of FVIII cofactor function replacement activity in bispecific antibodies with a combination of H and L chain modifications is shown.

[0269] Figure 4-2 The concentration dependence of FVIII cofactor function replacement activity in bispecific antibodies with a combination of H and L chain modifications is shown.

[0270] Figure 5 Shown is the maximum amount (peak height) of thrombin generation by bispecific antibodies having a combination of H chain and L chain modifications in a thrombin generation assay.

[0271] Figure 6 The ECM binding of the prepared bispecific antibodies is shown.

[0272] Figure 7 The antibody PK of the prepared bispecific antibodies is shown.

[0273] Figure 8 Shows the types of mismatches that may be expressed.

[0274] Figure 9-1 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0275] Figure 9-2 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0276] Figure 9-3Data from CIEX analysis of prepared bispecific antibodies are shown.

[0277] Figure 9-4 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0278] Figure 9-5 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0279] Figure 9-6 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0280] Figure 9-7 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0281] Figure 9-8 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0282] Figure 9-9 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0283] Figure 9-10 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0284] Figure 9-11 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0285] Figure 9-12 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0286] Figure 9-13 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0287] Figure 9-14 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0288] Figure 9-15 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0289] Figure 9-16 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0290] Figure 9-17 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0291] Figure 9-18 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0292] Figure 9-19 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0293] Figure 9-20 Data from CIEX analysis of prepared bispecific antibodies are shown.

[0294] Fig.10 The results of measuring the FVIII cofactor function replacement activity of the bispecific antibody having a novel L chain are shown.

[0295] Mode for Carrying Out the Invention

[0296] I. Definitions:

[0297] "Acceptor human framework" for the purposes of this article is a framework comprising an amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.

[0298] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (partner) (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd). Affinity can be determined by conventional methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for determining binding affinity are described below.

[0299] An "affinity matured" antibody is one with one or more alterations in one or more hypervariable regions (HVRs) which result in an improvement in the affinity of the antibody for antigen compared to a parent antibody which does not possess such alteration.

[0300] The multispecific antigen-binding molecules described herein comprise a first antigen-binding site and a second antigen-binding site, which can specifically bind to at least two different types of antigens.

[0301] In one embodiment, the first antigen binding site and the second antigen binding site are only required to have the activity of binding to coagulation factor IX (FIX) and / or activated coagulation factor IX (FIXa), and coagulation factor X (FX), respectively, and examples include sites necessary for binding to antigens, such as antibodies, scaffold molecules (antibody-like molecules), or peptides, or fragments containing these sites. Scaffold molecules are molecules that exhibit function by binding to target molecules, and any polypeptides can be used as long as they are conformationally stable polypeptides that can bind to at least one target antigen. Examples of such polypeptides include antibody variable regions, fibronectin (WO 2002 / 032925), protein A domain (WO 1995 / 001937), LDL receptor A domain (WO 2004 / 044011, WO 2005 / 040229), ankyrin (WO 2002 / 020565), etc., as well as molecules described in the literature by Nygren et al. (Current Opinion in Structural Biology, 7:463-469 (1997); and Journal of Immunol Methods, 290:3-28 (2004)), Binz et al. (Nature Biotech 23:1257-1266 (2005)), and Hosse et al. (Protein Science 15:14-27 (2006)). In addition, peptide molecules that can bind to a target antigen may be used as described in Curr Opin Mol Ther. 2010 Aug; 12(4): 487-95 and Drugs. 2008; 68(7): 901-12.

[0302] The polypeptides in the present invention generally refer to proteins and peptides having a length of about ten amino acids or longer. Polypeptides are generally derived from organisms, but are not particularly limited thereto, and for example, they may consist of artificially designed sequences. They may also be any naturally occurring polypeptide, or a synthetic polypeptide, a recombinant polypeptide, or the like. In addition, fragments of the above-mentioned polypeptides are also included in the polypeptides of the present invention.

[0303] In one embodiment, examples of multispecific antigen-binding molecules include multispecific antibodies that can specifically bind to at least two different antigens or two different epitopes on the same antigen.

[0304] In one embodiment, the multispecific antibodies of the invention are bispecific antibodies (BsAbs) (they may also be referred to as dual specific antibodies).

[0305] Herein, the terms "FVIII cofactor function replacement activity", "FVIII replacement activity", and "activity that replaces the function of FVIII" are used synonymously and refer to the activity of binding to FIX and / or FIXa and FX to promote the activation of FX (promoting the generation of activated coagulation factor X (FXa)).

[0306] In one embodiment, the multispecific antigen-binding molecule having FVIII cofactor function replacement activity is a multispecific antigen-binding molecule that binds to FIX and / or FIXa and FX.

[0307] In certain embodiments, the multispecific antigen binding molecule having FVIII cofactor function replacement activity is a multispecific antibody that binds to FIX and / or FIXa and FX. In another specific embodiment, the multispecific antibody that binds to FIX and / or FIXa and FX is a bispecific antibody that binds to FIX and / or FIXa and FX.

[0308] The term "bispecific antibody that binds to FIX and / or FIXa and FX" refers to a bispecific antibody that can bind to FIX and / or FIXa and FX with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent targeting FIX and / or FIXa and FX. In one embodiment, the extent of binding of the FIX and / or FIXa-binding and FX-binding bispecific antibody to an unrelated non-FIX protein, a non-FIXa protein, or a non-FX protein is less than 10% of the binding of the antibody to FIX and / or FIXa and FX, as determined (e.g., by radioimmunoassay (RIA)). In certain embodiments, the FIX and / or FIXa-binding and FX-binding antibody has an affinity of 100 μM or less, 10 μM or less, 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or less, or 0.001 nM or less (e.g., 10 -5 M or smaller, e.g. 10 - 5 M to 10 -10 M, for example 10 -6 M to 10 -10 In certain embodiments, the bispecific antibody that binds to FIX and / or FIXa and FX binds to an epitope in FIX, FIXa and FX that is conserved in FIX from different species, in FIXa and in FX, respectively.

[0309] In the present invention, in certain embodiments, the term "antibody" is used synonymously with "antigen binding molecule". In the present invention, the terms "antibody" and "antigen binding molecule" are used in the broadest sense, and include monoclonal antibodies, polyclonal antibodies and antibody variants (such as chimeric antibodies, humanized antibodies, microantibodies (low molecular weight antibodies) (including antibody fragments to which other molecules can be added arbitrarily) and multispecific antibodies), as long as they show the desired antigen binding activity or biological activity. Examples of "antibodies" or "antigen binding molecules" in the present invention include molecules in which the HAS binding scaffold has been added to Fab (wherein only the Fab portion is a normal antibody). In addition, in the present invention, "antibody" may also be a polypeptide or a heteropolymer (heteromeric) polymer. Preferred antibodies are monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, Fc fusion antibodies and microantibodies, such as antibody fragments.

[0310] As used herein, the term "antibody" refers to a binding protein that contains an antigen binding site. As used herein, the terms "binding site" and "antigen binding site" refer to the region of an antibody molecule to which an antigen actually binds. The term "antigen binding site" includes an antibody heavy chain variable domain (VH) and an antibody light chain variable domain (VL) (VH / VL pair).

[0311] "Antibody fragment" refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0312] An "antibody that binds to the same epitope as a reference antibody" refers to an antibody that blocks the binding of the reference antibody to its antigen by 50% or more in a competition assay, and conversely, the reference antibody blocks the binding of the antibody to its antigen by 50% or more in a competition assay. Exemplary competition assays are provided herein.

[0313] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0314] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0315] An "effective amount" of an agent (eg, a pharmaceutical formulation) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0316] The term "Fc region" herein is used to define the C-terminal region of the immunoglobulin heavy chain containing at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl end of the heavy chain. However, the C-terminal lysine (Lys447) or glycine-lysine (Gly446-Lys447) in the Fc region may be present or absent. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0317] "Framework" or "FR" refers to the variable domain residues other than the hypervariable region (HVR) residues. The FR of the variable domain is generally composed of four FR domains: FR1, FR2, FR3 and FR4. Therefore, in VH (or VL), HVR and FR sequences generally appear in the following order: FR1-H1 (L1)-FR2-H2 (L2)-FR3-H3 (L3)-FR4.

[0318] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0319] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical to their parent cell nucleic acid content, but may contain mutations. Mutant progeny having the same function or biological activity as screened or selected in the initial transformed cell are included herein.

[0320] "Human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human source utilizing a human antibody repertoire or other human antibody encoding sequence. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.

[0321] A "human consensus framework" is a framework that represents the most frequently occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup such as Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols.1-3. In one embodiment, for VL, the subgroup is subgroup κI as described by Kabat et al., supra. In one embodiment, for VH, the subgroup is subgroup III as described by Kabat et al., supra.

[0322] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and usually two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of non-human antibodies, and all or substantially all of the FRs correspond to those of human antibodies. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization.

[0323] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence ("complementarity determining region" or "CDR") and / or forms structurally defined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contacts"). Typically, an antibody comprises six HVRs: three in VH (H1, H2, H3), and three in VL (L1, L2, L3). Exemplary HVRs herein include:

[0324] (a) hypervariable loops present at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));

[0325] (b) CDRs present at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991));

[0326] (c) antigenic contacts present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and

[0327] (d) a combination of (a), (b) and / or (c), comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).

[0328] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al. supra.

[0329] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to cytotoxic agents.

[0330] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0331] An "isolated" antibody is one that has been separated from the components of its natural environment. In some embodiments, the antibody is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0332] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0333] "Isolated nucleic acid encoding a bispecific antibody that binds to FIX and / or FIXa and FX" refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present in one or more locations in a host cell.

[0334] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homologous antibodies, that is, the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible variant antibodies, for example, containing naturally occurring mutations or produced during the monoclonal antibody preparation, such variants are usually present in small amounts. In contrast to polyclonal antibody preparations (usually including different antibodies for different determinants (epitopes)), each monoclonal antibody in a monoclonal antibody preparation is for a single determinant on an antigen. Therefore, the modifier "monoclonal" indicates that the antibody is characterized by being obtained from a substantially uniform antibody population, and is not interpreted as requiring the antibody to be produced by any particular method. For example, the monoclonal antibody used in accordance with the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0335] "Natural antibodies" refer to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains bound by disulfide bonds. From N- to C-, each heavy chain has a variable region (VH), also referred to as a variable heavy chain domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-, each light chain has a variable region (VL), also referred to as a variable light chain domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody can be assigned to one of two types based on the amino acid sequence of its constant domain, referred to as κ (κ) and λ (λ).

[0336] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0337] " Percentage (%) amino acid sequence identity " with respect to reference polypeptide sequence is defined as the percentage of the amino acid residues in the candidate sequence identical with the amino acid residues in the reference polypeptide sequence after comparing sequences and, if necessary, introducing spaces to achieve maximum percentage sequence identity, and not considering any conservative substitutions as a part of sequence identity. The comparison for the purpose of determining amino acid sequence identity percentage can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR) software or GENETYX (registered trademark) (Genetyx Co., Ltd.). Those skilled in the art can determine the appropriate parameters for comparing sequences, including any algorithm required for achieving maximum comparison on the full length of the sequence compared.

[0338] The ALIGN-2 sequence comparison computer program is written by Genentech, Inc., and the source code has been submitted to the U.S. Copyright Office (Washington, D.C., 20559) together with the user files, and it is registered with U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. in South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system (including digital UNIX V4.0D). All sequence comparison parameters are set by the ALIGN-2 program and are unchanged. In the case of using ALIGN-2 to compare amino acid sequences, the % amino acid sequence identity of a given amino acid sequence A to, with, or for a given amino acid sequence B (which can alternatively be expressed as having or comprising a given amino acid sequence A to, with, or for a given amino acid sequence B certain % amino acid sequence identity) is calculated as follows:

[0339] 100 times the fraction X / Y

[0340] wherein X is the number of amino acid residues that score as identical matches in the program alignment of A and B by the sequence alignment program ALIGN-2, and wherein Y is the total number of amino acid residues in B. It will be understood that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values ​​used herein are obtained as described in the preceding paragraph using the ALIGN-2 computer program.

[0341] The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of the active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[0342] "Pharmaceutically acceptable carrier" refers to ingredients in a pharmaceutical preparation other than the active ingredient, which are non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.

[0343] Unless otherwise indicated, as used herein, the terms "FIX", "FIXa" and "FX" refer to any native "FIX", "FIXa" and native "FX" from any vertebrate source, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats). The terms encompass "full-length" unprocessed "FIX", "FIXa" and "FX" as well as any form of "FIX", "FIXa" and "FX" derived from processing in cells. The terms also encompass naturally occurring variants of "FIX", "FIXa" and "FX", such as splice variants or allelic variants.

[0344] As used herein, "treatment" (and grammatical variations such as "treat" or "treating") refers to clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed for prevention or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, eliminating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and eliminating or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the development of the disease or to slow the progression of the disease.

[0345] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain involved in antibody binding to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies generally have similar structures, each domain comprising 4 conserved framework regions (FR) and 3 hypervariable regions (HVR). (See, e.g., Kindt et al., Kuby Immunology, 6th edition, WH Freeman and Co., p. 91 (2007).). A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, a library of complementary VL or VH domains can be screened using the VH or VL domains of antibodies that bind to an antigen, respectively, to isolate antibodies that bind to a specific antigen. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).

[0346] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."

[0347] II. Composition and Methods

[0348] On the one hand, the present invention is based in part on multispecific antigen binding molecules with FVIII cofactor function replacement activity. In certain embodiments, multispecific antigen binding molecules that bind to FIX and / or FIXa and FX are provided. The multispecific antigen binding molecules of the present invention can be used, for example, to treat bleeding, diseases involving bleeding, or diseases caused by bleeding.

[0349] A. Exemplary multispecific antigen-binding molecules that bind to FIX and / or FIXa and FX.

[0350] On the one hand, the invention provides an isolated multispecific antigen-binding molecule that binds to FIX and / or FIXa and FX. In certain embodiments, the multispecific antigen-binding molecule is a bispecific antibody that binds to FIX and / or FIXa and FX, and such bispecific antibody has FVIII cofactor function replacement activity.

[0351] The bispecific antibody ACE910 (emicizumab) that binds to FIX and / or FIXa and FX is an antibody described in patent literature (WO 2012 / 067176) and described below.

[0352] The antibody is a bispecific antibody, wherein the first polypeptide and the third polypeptide are associated and the second polypeptide and the fourth polypeptide are associated, the bispecific antibody comprising a first polypeptide, which is an H chain comprising the HVR-H1, HVR-H2 and HVR-H3 amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively (H chain CDR of Q499); a second polypeptide, which is an H chain comprising the HVR-H1, HVR-H2 and HVR-H3 amino acid sequences of SEQ ID NOs: 4, 5 and 6, respectively (H chain CDR of J327); and a third and fourth polypeptide, which are shared L chains comprising the HVR-L1, HVR-L2 and HVR-L3 amino acid sequences of SEQ ID NOs: 7, 8 and 9, respectively (L chain CDR of L404).

[0353] More specifically, the antibody is a bispecific antibody in which the first polypeptide and the third polypeptide are associated and the second polypeptide and the fourth polypeptide are associated, the bispecific antibody comprising the first polypeptide, which is an H chain containing the H chain variable region amino acid sequence of SEQ ID NO: 45; the second polypeptide, which is an H chain containing the H chain variable region amino acid sequence of SEQ ID NO: 46; and the third and fourth polypeptides, which are shared L chains containing the L chain variable region amino acid sequence of SEQ ID NO: 47.

[0354] More specifically, the antibody is a bispecific antibody in which the first polypeptide and the third polypeptide are associated and the second polypeptide and the fourth polypeptide are associated, the bispecific antibody comprising the first polypeptide, which is an H chain consisting of the amino acid sequence of SEQ ID NO: 10; the second polypeptide, which is an H chain consisting of the amino acid sequence of SEQ ID NO: 11; and the third and fourth polypeptides, which are shared L chains (Q499-z121 / J327-z119 / L404-k) consisting of the amino acid sequence of SEQ ID NO: 12.

[0355] The multispecific antigen-binding molecule of the present invention is a multispecific antigen-binding molecule having the function of replacing the function of FVIII, wherein the molecule comprises a first antigen-binding site that binds to FIX and / or FIXa, and a second antigen-binding site that binds to FX,

[0356] wherein the first antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0357] wherein the heavy chain variable domain (Q499) comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and

[0358] The light chain variable domain (QNK131) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 162, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 163, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 164, and

[0359] wherein the second antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0360] wherein the heavy chain variable domain (J327) comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 4, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6, and

[0361] The light chain variable domain (JNL095) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 165, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 166, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 167;

[0362] In at least one HVR, one or more amino acid residues are substituted by, deleted or inserted into other amino acids.

[0363] In certain embodiments, the multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule that has the function of replacing the function of FVIII.

[0364] In addition, in other embodiments, the multispecific antigen-binding molecule of the present invention is a multispecific antigen-binding molecule with reduced reactivity compared to ACE910 (Emicizumab) idiotype antibody. In this article, the phrase "compared to ACE910 (Emicizumab), with anti-ACE910 (Emicizumab) idiotype antibody has reduced reactivity" refers to when the binding strength (%) between the anti-idiotype antibody and the labeled ACE910 is measured using the method described in Example 1, and if the concentration of the antibody to be determined is 100 μg / mL, the binding strength is preferably reduced by 10% or more, more preferably by 20% or more, and still more preferably by 30% or more.

[0365] Furthermore, in other embodiments, the multispecific antigen-binding molecule is a multispecific antigen-binding molecule having enhanced FVIII cofactor function replacement activity and higher activity compared to ACE910 (emicizumab) even at low antibody concentrations.

[0366] In other embodiments, compared to ACE910 (Amicizumab), the multispecific antigen binding molecule has substantially no FIX activation inhibitory activity and has increased FVIII cofactor function substitution activity. In this article, "substantially no FIX activation inhibitory activity" means that when the OD value is determined using the method shown in the examples, the OD value is reduced by 0.025 or less, preferably 0.02 or less, and more preferably 0.01 or less compared to the control OD value.

[0367] In one embodiment, the heavy chain variable domain of the first antigen-binding site of the multispecific antigen-binding molecule of the present invention is a heavy chain variable domain of the first antigen-binding site, wherein in the heavy chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 97, 98, 100, 100a, 100b and 100e according to Kabat numbering is substituted by another amino acid or is deleted.

[0368] In one embodiment, the light chain variable domain of the first antigen binding site of the present invention is the light chain variable domain of the first antigen binding site, wherein in the light chain variable domain of the first antigen binding site, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 53, 55, 92, 93, 95 and 96 according to Kabat numbering is substituted or inserted by another amino acid.

[0369] In one embodiment, the heavy chain variable domain of the second antigen binding site of the present invention is a heavy chain variable domain of the second antigen binding site, wherein in the heavy chain variable domain of the second antigen binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 51, 56, 57, 59, 61, 62, 65 and 102 according to Kabat numbering is substituted by another amino acid.

[0370] In one embodiment, the light chain variable domain of the second antigen binding site of the present invention is a light chain variable domain of the second antigen binding site, wherein in the light chain variable domain of the second antigen binding site, at least one amino acid residue selected from the amino acid residues at positions 24, 26, 27, 29, 30, 31, 32, 50, 92, 94, 95, 95a and 96 according to Kabat numbering is substituted by another amino acid or is deleted.

[0371] In one embodiment, a multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule wherein:

[0372] In the heavy chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 97, 98, 100, 100a, 100b and 100e according to Kabat numbering is substituted by another amino acid or is deleted,

[0373] In the light chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 53, 55, 92, 93, 95 and 96 according to Kabat numbering is substituted or inserted by another amino acid,

[0374] In the heavy chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 51, 56, 57, 59, 61, 62, 65 and 102 according to Kabat numbering is substituted by another amino acid, and

[0375] In the light chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 24, 26, 27, 29, 30, 31, 32, 50, 92, 94, 95, 95a and 96 according to Kabat numbering is substituted by another amino acid or is deleted.

[0376] In one embodiment, the heavy chain variable domain of the first antigen binding site of a multispecific antigen binding molecule of the invention is the heavy chain variable domain of said first antigen binding site, wherein:

[0377] In the heavy chain variable domain of the first antigen-binding site, the amino acid residue at position 31 is histidine, the amino acid residue at position 34 is alanine, the amino acid residue at position 97 is aspartic acid, the amino acid residue at position 98 is serine, the amino acid residue at position 100 is aspartic acid or glutamic acid, the amino acid residue at position 100a is aspartic acid or is missing, the amino acid residue at position 100b is alanine or histidine, or the amino acid residue at position 100e is histidine or isoleucine, the positions being numbered according to Kabat.

[0378] In one embodiment, the light chain variable domain of the first antigen binding site of the invention is the light chain variable domain of said first antigen binding site, wherein:

[0379] In the light chain variable domain of the first antigen-binding site, the amino acid residue at position 26 is threonine, the amino acid residue at position 27 is arginine, the amino acid residue at position 30 is arginine, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is aspartic acid or glutamic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 92 is arginine, the amino acid residue at position 93 is serine or aspartic acid, the amino acid residue at position 95 is proline, or the amino acid residue at position 96 is glycine, the positions being numbered according to Kabat.

[0380] In one embodiment, the heavy chain variable domain of the second antigen binding site of the invention is the heavy chain variable domain of the second antigen binding site, wherein:

[0381] In the heavy chain variable domain of the second antigen-binding site, the amino acid residue at position 31 is asparagine, glutamine or histidine, the amino acid residue at position 51 is serine, the amino acid residue at position 56 is threonine or arginine, the amino acid residue at position 57 is valine, the amino acid residue at position 59 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is lysine, the amino acid residue at position 65 is asparagine or glutamine, or the amino acid residue at position 102 is valine, the positions being numbered according to Kabat.

[0382] In one embodiment, the light chain variable domain of the second antigen binding site of the invention is the light chain variable domain of the second antigen binding site, wherein:

[0383] In the light chain variable domain of the second antigen-binding site, the amino acid residue at position 24 is threonine, the amino acid residue at position 26 is glutamic acid, the amino acid residue at position 27 is glutamine, the amino acid residue at position 29 is serine, the amino acid residue at position 30 is glutamine, serine or glutamic acid, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is glutamine or glutamic acid, the amino acid residue at position 50 is glutamine, the amino acid residue at position 92 is alanine, the amino acid residue at position 94 is aspartic acid, the amino acid residue at position 95 is aspartic acid or alanine, the amino acid residue at position 95a is tyrosine or is missing, or the amino acid residue at position 96 is threonine, the positions being numbered according to Kabat.

[0384] In one embodiment, a multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule wherein:

[0385] in the heavy chain variable domain of the first antigen-binding site, the amino acid residue at position 31 is histidine, the amino acid residue at position 34 is alanine, the amino acid residue at position 97 is aspartic acid, the amino acid residue at position 98 is serine, the amino acid residue at position 100 is aspartic acid or glutamic acid, the amino acid residue at position 100a is aspartic acid or is missing, the amino acid residue at position 100b is alanine or histidine, or the amino acid residue at position 100e is histidine or isoleucine, the positions being numbered according to Kabat;

[0386] in the light chain variable domain of the first antigen-binding site, the amino acid residue at position 26 is threonine, the amino acid residue at position 27 is arginine, the amino acid residue at position 30 is arginine, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is aspartic acid or glutamic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 92 is arginine, the amino acid residue at position 93 is serine or aspartic acid, the amino acid residue at position 95 is proline, or the amino acid residue at position 96 is glycine, the positions being numbered according to Kabat;

[0387] in the heavy chain variable domain of the second antigen-binding site, the amino acid residue at position 31 is asparagine, glutamine or histidine, the amino acid residue at position 51 is serine, the amino acid residue at position 56 is threonine or arginine, the amino acid residue at position 57 is valine, the amino acid residue at position 59 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is lysine, the amino acid residue at position 65 is asparagine or glutamine, or the amino acid residue at position 102 is valine, the positions being numbered according to Kabat; and

[0388] In the light chain variable domain of the second antigen-binding site, the amino acid residue at position 24 is threonine, the amino acid residue at position 26 is glutamic acid, the amino acid residue at position 27 is glutamine, the amino acid residue at position 29 is serine, the amino acid residue at position 30 is glutamine, serine or glutamic acid, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is glutamine or glutamic acid, the amino acid residue at position 50 is glutamine, the amino acid residue at position 92 is alanine, the amino acid residue at position 94 is aspartic acid, the amino acid residue at position 95 is aspartic acid or alanine, the amino acid residue at position 95a is tyrosine or is missing, or the amino acid residue at position 96 is threonine, the positions being numbered according to Kabat.

[0389] In one embodiment, the heavy chain variable domain of the first antigen binding site of a multispecific antigen-binding molecule of the invention is a heavy chain variable domain comprising:

[0390] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 168, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 169, and HVR-H3 (QH01) comprising the amino acid sequence of SEQ ID NO: 170;

[0391] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 171, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 172, and HVR-H3 (QH02) comprising the amino acid sequence of SEQ ID NO: 173;

[0392] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 174, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 175, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 176 (QH03);

[0393] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 177, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 178, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 179 (QH04);

[0394] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 180, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 181, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 182 (QH06); or

[0395] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO:183, HVR-H2 comprising the amino acid sequence of SEQ ID NO:184, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:185 (QH07).

[0396] In one embodiment, the light chain variable domain of the first antigen binding site of a multispecific antigen-binding molecule of the invention is a light chain variable domain comprising:

[0397] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 186, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 187, and HVR-L3 (QL21) comprising the amino acid sequence of SEQ ID NO: 188;

[0398] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 189, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 190, and HVR-L3 (QL22) comprising the amino acid sequence of SEQ ID NO: 191;

[0399] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 192, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 193, and HVR-L3 (QL23) comprising the amino acid sequence of SEQ ID NO: 194;

[0400] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 195, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 196, and HVR-L3 (QL24) comprising the amino acid sequence of SEQ ID NO: 197;

[0401] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 198, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 199, and HVR-L3 (QL25) comprising the amino acid sequence of SEQ ID NO: 200;

[0402] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO:201, HVR-L2 comprising the amino acid sequence of SEQ ID NO:202, and HVR-L3 (QL26) comprising the amino acid sequence of SEQ ID NO:203;

[0403] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO:204, HVR-L2 comprising the amino acid sequence of SEQ ID NO:205, and HVR-L3 (QL28) comprising the amino acid sequence of SEQ ID NO:206;

[0404] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO:207, HVR-L2 comprising the amino acid sequence of SEQ ID NO:208, and HVR-L3 (QL29) comprising the amino acid sequence of SEQ ID NO:209;

[0405] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO:210, HVR-L2 comprising the amino acid sequence of SEQ ID NO:211, and HVR-L3 (QL30) comprising the amino acid sequence of SEQ ID NO:212;

[0406] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO:213, HVR-L2 comprising the amino acid sequence of SEQ ID NO:214, and HVR-L3 (QL31) comprising the amino acid sequence of SEQ ID NO:215;

[0407] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO:216, HVR-L2 comprising the amino acid sequence of SEQ ID NO:217, and HVR-L3 (QL32) comprising the amino acid sequence of SEQ ID NO:218; or

[0408] 12) HVR-L1 comprising the amino acid sequence of SEQ ID NO:219, HVR-L2 comprising the amino acid sequence of SEQ ID NO:220, and HVR-L3 (QL33) comprising the amino acid sequence of SEQ ID NO:221.

[0409] In one embodiment, the heavy chain variable domain of the second antigen binding site of the multispecific antigen-binding molecule of the invention is a heavy chain variable domain comprising:

[0410] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 222, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 223, and HVR-H3 (JH01) comprising the amino acid sequence of SEQ ID NO: 224;

[0411] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 225, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 226, and HVR-H3 (JH02) comprising the amino acid sequence of SEQ ID NO: 227;

[0412] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 228, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 229, and HVR-H3 (JH03) comprising the amino acid sequence of SEQ ID NO: 230;

[0413] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO:231, HVR-H2 comprising the amino acid sequence of SEQ ID NO:232, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:233 (JH04);

[0414] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 234, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 235, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 236 (JH05);

[0415] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 237, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 238, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 239 (JH06);

[0416] 7) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 240, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 241, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 242 (JH07);

[0417] 8) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 243, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 244, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 245 (JH08);

[0418] 9) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 246, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 247, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 248 (JH09);

[0419] 10) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 249, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 250, and HVR-H3 (JH10) comprising the amino acid sequence of SEQ ID NO: 251; or

[0420] 11) HVR-H1 comprising the amino acid sequence of SEQ ID NO:252, HVR-H2 comprising the amino acid sequence of SEQ ID NO:253, and HVR-H3 (JH11) comprising the amino acid sequence of SEQ ID NO:254.

[0421] In one embodiment, the light chain variable domain of the second antigen binding site of a multispecific antigen-binding molecule of the invention is a light chain variable domain comprising:

[0422] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 255, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 256, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 257 (JL01);

[0423] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 258, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 259, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 260 (JL02);

[0424] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 261, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 262, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 263 (JL03);

[0425] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 264, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 265, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 266 (JL04);

[0426] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 267, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 268, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 269 (JL05);

[0427] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 270, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 271, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 272 (JL06);

[0428] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 273, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 274, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 275 (JL07);

[0429] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 276, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 277, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 278 (JL08);

[0430] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 279, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 280, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 281 (JL09);

[0431] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 282, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 283, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 284 (JL10); or

[0432] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO:285, HVR-L2 comprising the amino acid sequence of SEQ ID NO:286, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:287 (JL11).

[0433] In one embodiment, the multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule, wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises:

[0434] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 168, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 169, and HVR-H3 (QH01) comprising the amino acid sequence of SEQ ID NO: 170;

[0435] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 171, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 172, and HVR-H3 (QH02) comprising the amino acid sequence of SEQ ID NO: 173;

[0436] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 174, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 175, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 176 (QH03);

[0437] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 177, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 178, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 179 (QH04);

[0438] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 180, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 181, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 182 (QH06); or

[0439] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 183, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 184, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 185 (QH07); and

[0440] The light chain variable domain comprises:

[0441] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 186, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 187, and HVR-L3 (QL21) comprising the amino acid sequence of SEQ ID NO: 188;

[0442] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 189, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 190, and HVR-L3 (QL22) comprising the amino acid sequence of SEQ ID NO: 191;

[0443] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 192, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 193, and HVR-L3 (QL23) comprising the amino acid sequence of SEQ ID NO: 194;

[0444] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 195, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 196, and HVR-L3 (QL24) comprising the amino acid sequence of SEQ ID NO: 197;

[0445] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 198, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 199, and HVR-L3 (QL25) comprising the amino acid sequence of SEQ ID NO: 200;

[0446] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO:201, HVR-L2 comprising the amino acid sequence of SEQ ID NO:202, and HVR-L3 (QL26) comprising the amino acid sequence of SEQ ID NO:203;

[0447] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO:204, HVR-L2 comprising the amino acid sequence of SEQ ID NO:205, and HVR-L3 (QL28) comprising the amino acid sequence of SEQ ID NO:206;

[0448] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO:207, HVR-L2 comprising the amino acid sequence of SEQ ID NO:208, and HVR-L3 (QL29) comprising the amino acid sequence of SEQ ID NO:209;

[0449] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO:210, HVR-L2 comprising the amino acid sequence of SEQ ID NO:211, and HVR-L3 (QL30) comprising the amino acid sequence of SEQ ID NO:212;

[0450] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO:213, HVR-L2 comprising the amino acid sequence of SEQ ID NO:214, and HVR-L3 (QL31) comprising the amino acid sequence of SEQ ID NO:215;

[0451] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO:216, HVR-L2 comprising the amino acid sequence of SEQ ID NO:217, and HVR-L3 (QL32) comprising the amino acid sequence of SEQ ID NO:218; or

[0452] 12) HVR-L1 comprising the amino acid sequence of SEQ ID NO:219, HVR-L2 comprising the amino acid sequence of SEQ ID NO:220, and HVR-L3 (QL33) comprising the amino acid sequence of SEQ ID NO:221; and

[0453] wherein the second antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0454] Wherein the heavy chain variable domain comprises:

[0455] 1) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 222, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 223, and HVR-H3 (JH01) comprising the amino acid sequence of SEQ ID NO: 224;

[0456] 2) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 225, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 226, and HVR-H3 (JH02) comprising the amino acid sequence of SEQ ID NO: 227;

[0457] 3) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 228, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 229, and HVR-H3 (JH03) comprising the amino acid sequence of SEQ ID NO: 230;

[0458] 4) HVR-H1 comprising the amino acid sequence of SEQ ID NO:231, HVR-H2 comprising the amino acid sequence of SEQ ID NO:232, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:233 (JH04);

[0459] 5) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 234, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 235, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 236 (JH05);

[0460] 6) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 237, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 238, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 239 (JH06);

[0461] 7) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 240, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 241, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 242 (JH07);

[0462] 8) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 243, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 244, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 245 (JH08);

[0463] 9) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 246, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 247, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 248 (JH09);

[0464] 10) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 249, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 250, and HVR-H3 (JH10) comprising the amino acid sequence of SEQ ID NO: 251; or

[0465] 11) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 252, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 253, and HVR-H3 (JH11) comprising the amino acid sequence of SEQ ID NO: 254; and

[0466] The light chain variable domain comprises:

[0467] 1) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 255, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 256, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 257 (JL01);

[0468] 2) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 258, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 259, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 260 (JL02);

[0469] 3) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 261, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 262, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 263 (JL03);

[0470] 4) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 264, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 265, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 266 (JL04);

[0471] 5) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 267, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 268, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 269 (JL05);

[0472] 6) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 270, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 271, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 272 (JL06);

[0473] 7) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 273, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 274, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 275 (JL07);

[0474] 8) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 276, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 277, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 278 (JL08);

[0475] 9) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 279, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 280, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 281 (JL09);

[0476] 10) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 282, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 283, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 284 (JL10); or

[0477] 11) HVR-L1 comprising the amino acid sequence of SEQ ID NO:285, HVR-L2 comprising the amino acid sequence of SEQ ID NO:286, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:287 (JL11).

[0478] In one embodiment of the present invention, the multispecific antigen-binding molecule of the present invention is a multispecific antigen-binding molecule with the function of replacing the function of coagulation factor VIII, wherein the molecule comprises a first antigen-binding site that binds to coagulation factor IX and / or activated coagulation factor IX, and a second antigen-binding site that binds to coagulation factor X, wherein the first antigen-binding site comprises the heavy chain variable domain (Q499) of SEQ ID NO: 45 and the light chain variable domain (QNK131) of SEQ ID NO: 13, and the second antigen-binding site comprises the heavy chain variable domain (J327) of SEQ ID NO: 46 and the light chain variable domain (JNL095) of SEQ ID NO: 31, and wherein in at least one heavy chain variable domain or light chain variable domain, one or more amino acid residues are substituted or deleted by other amino acids.

[0479] In one embodiment, in the heavy chain variable domain of the first antigen binding site of the present invention, in the above-mentioned heavy chain variable domain of said first antigen binding site, according to Kabat numbering, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 39, 97, 98, 100, 100a, 100b and 100e is substituted by another amino acid or is deleted.

[0480] In one embodiment, in the light chain variable domain of the first antigen binding site of the present invention, in the above-mentioned light chain variable domain of said first antigen binding site, according to Kabat numbering, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 38, 45, 53, 55, 60, 70, 76, 79, 80, 83, 85, 92, 93, 95 and 96 is substituted or inserted by another amino acid.

[0481] In one embodiment, in the heavy chain variable domain of the second antigen binding site of the present invention, in the above-mentioned heavy chain variable domain of the second antigen binding site, at least one amino acid residue selected from the amino acid residues at positions 28, 31, 39, 51, 56, 57, 59, 61, 62, 65, 67, 73, 82b and 102 according to Kabat numbering is substituted by another amino acid.

[0482] In one embodiment, in the light chain variable domain of the second antigen binding site of the present invention, in the above-mentioned light chain variable domain of the second antigen binding site, according to Kabat numbering, at least one amino acid residue selected from the amino acid residues at positions 3, 8, 15, 24, 26, 27, 29, 30, 31, 32, 38, 48, 49, 50, 79, 92, 94, 95, 95a and 96 is substituted by another amino acid or is deleted.

[0483] In one embodiment, in the multispecific antigen-binding molecules of the invention:

[0484] In the heavy chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 31, 34, 39, 97, 98, 100, 100a, 100b and 100e is substituted by another amino acid or is deleted according to Kabat numbering;

[0485] In the above-mentioned light chain variable domain of the first antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 26, 27, 30, 31, 32, 38, 45, 53, 55, 60, 70, 76, 79, 80, 83, 85, 92, 93, 95 and 96 according to Kabat numbering is substituted or inserted by another amino acid;

[0486] In the heavy chain variable domain of the second antigen-binding site, at least one amino acid residue selected from the amino acid residues at positions 28, 31, 39, 51, 56, 57, 59, 61, 62, 65, 67, 73, 82b and 102 is substituted by another amino acid according to Kabat numbering; and

[0487] In the above-mentioned light chain variable domain of the second antigen binding site, according to Kabat numbering, at least one amino acid residue selected from the amino acid residues at positions 3, 8, 15, 24, 26, 27, 29, 30, 31, 32, 38, 48, 49, 50, 79, 92, 94, 95, 95a and 96 is substituted by another amino acid or is deleted.

[0488] In one embodiment, in the heavy chain variable domain of the first antigen binding site of the present invention, the amino acid residue at position 31 (according to Kabat numbering; the same applies to the following cases) is histidine; the amino acid residue at position 34 is alanine; the amino acid residue at position 39 is glutamic acid; the amino acid residue at position 97 is aspartic acid; the amino acid residue at position 98 is serine; the amino acid residue at position 100 is aspartic acid or glutamic acid; the amino acid residue at position 100a is aspartic acid or missing; the amino acid residue at position 100b is alanine or histidine; and the amino acid residue at position 100e is histidine or isoleucine, in the above-mentioned heavy chain variable domain of the first antigen binding site.

[0489] In one embodiment, in the light chain variable domain of the first antigen-binding site of the invention, the amino acid residue at position 26 (according to Kabat numbering; the same applies to the following) is threonine; the amino acid residue at position 27 is arginine; the amino acid residue at position 30 is arginine; the amino acid residue at position 31 is arginine; the amino acid residue at position 32 is aspartic acid or glutamic acid; the amino acid residue at position 38 is lysine; the amino acid residue at position 45 is glutamic acid; the amino acid residue at position 53 is arginine; the amino acid residue at position 55 is glutamic acid; the amino acid residue at position 60 is arginine; the amino acid residue at position 61 is arginine; the amino acid residue at position 62 is arginine; the amino acid residue at position 64 is arginine; the amino acid residue at position 65 is glutamic acid; the amino acid residue at position 66 is arginine; the amino acid residue at position 67 is arginine; the amino acid residue at position 68 is arginine; the amino acid residue at position 69 is arginine; the amino acid residue at position 70 is arginine; the amino acid residue at position 71 is arginine; the amino acid residue at position 72 is arginine; the amino acid residue at position 73 is arginine; the amino acid residue at position 74 is arginine; the amino acid residue at position 75 is arginine; the amino acid residue at position 76 is arginine; the amino acid residue at position 77 is arginine; the amino acid residue at position 78 is arginine; the amino acid residue at position 79 is arginine; the amino acid residue at position 80 is arginine; the amino acid residue at position 81 is arginine; the amino acid residue at position 82 is arg the amino acid residue at position 70 is aspartic acid; the amino acid residue at position 76 is asparagine; the amino acid residue at position 79 is glutamic acid; the amino acid residue at position 80 is proline or alanine; the amino acid residue at position 83 is methionine or alanine; the amino acid residue at position 85 is threonine; the amino acid residue at position 92 is arginine; the amino acid residue at position 93 is serine or aspartic acid; the amino acid residue at position 95 is proline; or the amino acid residue at position 96 is glycine, in the above-mentioned light chain variable domain of the first antigen binding site.

[0490] In one embodiment, in the heavy chain variable domain of the second antigen-binding site of the present invention, the amino acid residue at position 28 (according to Kabat numbering; the same applies to the following cases) is glutamic acid; the amino acid residue at position 31 is asparagine, glutamine or histidine; the amino acid residue at position 39 is lysine; the amino acid residue at position 51 is serine; the amino acid residue at position 56 is threonine or arginine; the amino acid residue at position 57 is valine; the amino acid residue at position 59 is serine; the amino acid residue at position 61 is arginine; the amino acid residue at position 62 is lysine; the amino acid residue at position 65 is asparagine or glutamine; the amino acid residue at position 67 is leucine; the amino acid residue at position 73 is isoleucine; the amino acid residue at position 82b is glutamic acid, or the amino acid residue at position 102 is valine, in the above-mentioned heavy chain variable domain of the second antigen-binding site.

[0491] In one embodiment, in the light chain variable domain of the second antigen-binding site of the invention, the amino acid residue at position 3 (according to Kabat numbering; the same applies to the following cases) is glutamic acid; the amino acid residue at position 8 is proline; the amino acid residue at position 15 is leucine; the amino acid residue at position 24 is threonine; the amino acid residue at position 26 is glutamic acid; the amino acid residue at position 27 is glutamine; the amino acid residue at position 29 is serine; the amino acid residue at position 30 is glutamine, serine, or glutamic acid; the amino acid residue at position 31 is arginine; the amino acid residue at position 32 is arginine. the amino acid residue at position is glutamine or glutamic acid; the amino acid residue at position 38 is glutamic acid; the amino acid residue at position 48 is isoleucine; the amino acid residue at position 49 is tyrosine; the amino acid residue at position 50 is glutamine; the amino acid residue at position 79 is glutamic acid; the amino acid residue at position 92 is alanine; the amino acid residue at position 94 is aspartic acid; the amino acid residue at position 95 is aspartic acid or alanine; the amino acid residue at position 95a is tyrosine or missing; or the amino acid residue at position 96 is threonine, in the above-mentioned light chain variable domain of the second antigen binding site.

[0492] In one embodiment, in the multispecific antigen-binding molecules of the invention:

[0493] in the above-mentioned heavy chain variable domain of said first antigen-binding site, the amino acid residue at position 31 (according to Kabat numbering; the same applies to the following cases) is histidine; the amino acid residue at position 34 is alanine; the amino acid residue at position 39 is glutamic acid; the amino acid residue at position 97 is aspartic acid; the amino acid residue at position 98 is serine; the amino acid residue at position 100 is aspartic acid or glutamic acid; the amino acid residue at position 100a is aspartic acid or is missing; the amino acid residue at position 100b is alanine or histidine; and the amino acid residue at position 100e is histidine or isoleucine;

[0494] In the above-mentioned light chain variable domain of the first antigen-binding site, the amino acid residue at position 26 (according to Kabat numbering; the same applies to the following cases) is threonine; the amino acid residue at position 27 is arginine; the amino acid residue at position 30 is arginine; the amino acid residue at position 31 is arginine; the amino acid residue at position 32 is aspartic acid or glutamic acid; the amino acid residue at position 38 is lysine; the amino acid residue at position 45 is glutamic acid; the amino acid residue at position 53 is arginine; the amino acid residue at position 55 is glutamic acid; and the amino acid residue at position 60 is arginine. the amino acid residue at position 60 is aspartic acid; the amino acid residue at position 70 is aspartic acid; the amino acid residue at position 76 is asparagine; the amino acid residue at position 79 is glutamic acid; the amino acid residue at position 80 is proline or alanine; the amino acid residue at position 83 is methionine or alanine; the amino acid residue at position 85 is threonine; the amino acid residue at position 92 is arginine; the amino acid residue at position 93 is serine or aspartic acid; the amino acid residue at position 95 is proline; or the amino acid residue at position 96 is glycine;

[0495] In the above-mentioned heavy chain variable domain of the second antigen-binding site, the amino acid residue at position 28 (according to Kabat numbering; the same applies to the following cases) is glutamic acid; the amino acid residue at position 31 is asparagine, glutamine or histidine; the amino acid residue at position 39 is lysine; the amino acid residue at position 51 is serine; the amino acid residue at position 56 is threonine or arginine; the amino acid residue at position 57 is valine; the amino acid residue at position 59 is serine; the amino acid residue at position 61 is arginine; the amino acid residue at position 62 is lysine; the amino acid residue at position 65 is asparagine or glutamine; the amino acid residue at position 67 is leucine; the amino acid residue at position 73 is isoleucine; the amino acid residue at position 82b is glutamic acid, or the amino acid residue at position 102 is valine;

[0496] In the above-mentioned light chain variable domain of the second antigen-binding site, the amino acid residue at position 3 (according to Kabat numbering; the same applies to the following cases) is glutamic acid; the amino acid residue at position 8 is proline; the amino acid residue at position 15 is leucine; the amino acid residue at position 24 is threonine; the amino acid residue at position 26 is glutamic acid; the amino acid residue at position 27 is glutamine; the amino acid residue at position 29 is serine; the amino acid residue at position 30 is glutamine, serine, or glutamic acid; the amino acid residue at position 31 is arginine ; the amino acid residue at position 32 is glutamine or glutamic acid; the amino acid residue at position 38 is glutamic acid; the amino acid residue at position 48 is isoleucine; the amino acid residue at position 49 is tyrosine; the amino acid residue at position 50 is glutamine; the amino acid residue at position 79 is glutamic acid; the amino acid residue at position 92 is alanine; the amino acid residue at position 94 is aspartic acid; the amino acid residue at position 95 is aspartic acid or alanine; the amino acid residue at position 95a is tyrosine or is missing; or the amino acid residue at position 96 is threonine.

[0497] In one embodiment, the heavy chain variable domain of the first antigen binding site of the multispecific antigen-binding molecule of the invention is a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, or SEQ ID NO:60.

[0498] In one embodiment, the light chain variable domain of the first antigen binding site of the multispecific antigen-binding molecule of the invention is a light chain variable domain comprising the amino acid sequence of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, or SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72.

[0499] In one embodiment, the heavy chain variable domain of the second antigen binding site of the multispecific antigen-binding molecule of the invention is a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, or SEQ ID NO:83.

[0500] In one embodiment, the light chain variable domain of the second antigen binding site of the multispecific antigen-binding molecule of the invention is a light chain variable domain comprising the amino acid sequence of SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, or SEQ ID NO:94.

[0501] In one embodiment, the multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule,

[0502] Wherein the first antigen binding site comprises:

[0503] a heavy chain variable domain (QH) of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, or SEQ ID NO:60; and

[0504] a light chain variable domain (QL) of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, or SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, or SEQ ID NO:72, and

[0505] Wherein the second antigen binding site comprises:

[0506] a heavy chain variable domain (JH) of SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, or SEQ ID NO:83; and

[0507] The light chain variable domain (JL) of SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, or SEQ ID NO:94.

[0508] In one embodiment, the present invention provides a multispecific antigen-binding molecule comprising a first antibody heavy chain variable domain and an antibody light chain variable domain that bind to FIX and / or FIXa, and a second antibody heavy chain variable domain and an antibody light chain variable domain that bind to FX, wherein the multispecific antigen-binding molecule is any one of the following (a) to (v):

[0509] (a) a multispecific antigen-binding molecule (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:56, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:61, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:84;

[0510] (b) a multispecific antigen-binding molecule (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:84;

[0511] (c) a multispecific antigen-binding molecule (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:63, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0512] (d) a multispecific antigen-binding molecule (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:64, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0513] (e) a multispecific antigen-binding molecule (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:75, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:86;

[0514] (f) a multispecific antigen-binding molecule (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 87;

[0515] (g) a multispecific antigen-binding molecule (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0516] (h) a multispecific antigen-binding molecule (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:65, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0517] (i) a multispecific antigen-binding molecule (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:85;

[0518] (j) a multispecific antigen-binding molecule (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0519] (k) a multispecific antigen-binding molecule (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0520] (l) a multispecific antigen-binding molecule (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:89;

[0521] (m) a multispecific antigen-binding molecule (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:88;

[0522] (n) a multispecific antigen-binding molecule (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:89;

[0523] (o) a multispecific antigen-binding molecule (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:90;

[0524] (p) a multispecific antigen-binding molecule (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:70, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:80, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:91;

[0525] (q) a multispecific antigen-binding molecule (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:90;

[0526] (r) a multispecific antigen-binding molecule (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:81, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:92;

[0527] (s) a multispecific antigen-binding molecule (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:82, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO:93;

[0528] (t) a multispecific antigen-binding molecule (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 105, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 72, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 83, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 94;

[0529] (u) a multispecific antigen-binding molecule that binds to the same epitope as the epitope in FIX and / or FIXa and the epitope in FX recognized by any one of the antibodies in (a) to (t);

[0530] (v) A multispecific antigen-binding molecule that competitively binds to an epitope in FIX and / or FIXa and an epitope in FX recognized by any one of the antibodies in (a) to (t).

[0531] In one embodiment, the heavy chain constant region of the multispecific antigen-binding molecule of the invention is a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:118 or SEQ ID NO:119.

[0532] In one embodiment, the light chain constant region of the multispecific antigen-binding molecule of the invention is a light chain constant region comprising the amino acid sequence of SEQ ID NO:100 or SEQ ID NO:102.

[0533] In one embodiment, the multispecific antigen-binding molecule of the invention is a multispecific antigen-binding molecule in which the first antigen-binding site comprises the constant region of (1) or (2) below, and the second antigen-binding site comprises the constant region of (1) or (2) below (not the constant region comprised in the first antigen-binding site):

[0534] (1) SEQ ID NO: 119 for the heavy chain constant region and SEQ ID NO: 100 for the light chain constant region;

[0535] (2) SEQ ID NO: 118 for the heavy chain constant region and SEQ ID NO: 102 for the light chain constant region.

[0536] In one embodiment, the multispecific antigen-binding molecule of the invention is a multispecific antibody. In a further embodiment, the multispecific antibody of the invention is a bispecific antibody.

[0537] In one embodiment, the present invention provides a bispecific antibody comprising a first antibody heavy chain variable domain and an antibody light chain variable domain that bind to FIX and / or FIXa, and a second antibody heavy chain variable domain and an antibody light chain variable domain that bind to FX, wherein the bispecific antibody is any one of the following (a) to (v):

[0538] (a) a bispecific antibody (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 56, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 61, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 84;

[0539] (b) a bispecific antibody (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 84;

[0540] (c) a bispecific antibody (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 63, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0541] (d) a bispecific antibody (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 64, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0542] (e) a bispecific antibody (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 75, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 86;

[0543] (f) a bispecific antibody (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 76, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 87;

[0544] (g) a bispecific antibody (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0545] (h) a bispecific antibody (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 65, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0546] (i) a bispecific antibody (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 85;

[0547] (j) a bispecific antibody (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0548] (k) a bispecific antibody (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0549] (l) a bispecific antibody (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 89;

[0550] (m) a bispecific antibody (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 88;

[0551] (n) a bispecific antibody (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 89;

[0552] (o) a bispecific antibody (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 90;

[0553] (p) a bispecific antibody (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 80, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 91;

[0554] (q) a bispecific antibody (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 90;

[0555] (r) a bispecific antibody (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 81, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 92;

[0556] (s) a bispecific antibody (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 82, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 93;

[0557] (t) a bispecific antibody (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 105, a first antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 72, a second antibody heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 83, and a second antibody light chain variable domain comprising the amino acid sequence of SEQ ID NO: 94;

[0558] (u) a bispecific antibody that binds to the same epitope as the epitope of coagulation factor IX and / or activated coagulation factor IX and the epitope of coagulation factor X recognized by any one of the antibodies of (a) to (t);

[0559] (v) A multispecific antigen-binding molecule that competitively binds to an epitope of coagulation factor IX and / or activated coagulation factor IX and an epitope of coagulation factor X recognized by any one of the antibodies of (a) to (t).

[0560] In one embodiment, the present invention provides a bispecific antibody comprising a first antibody heavy chain and an antibody light chain that bind to FIX and / or FIXa, and a second antibody heavy chain and an antibody light chain that bind to FX, wherein the bispecific antibody is any one of the following (a) to (v):

[0561] (a) a bispecific antibody (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 120, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 126, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149;

[0562] (b) a bispecific antibody (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149;

[0563] (c) a bispecific antibody (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 128, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0564] (d) a bispecific antibody (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 129, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0565] (e) a bispecific antibody (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 140, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 151;

[0566] (f) a bispecific antibody (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 141, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 152;

[0567] (g) a bispecific antibody (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0568] (h) a bispecific antibody (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 130, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0569] (i) a bispecific antibody (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150;

[0570] (j) a bispecific antibody (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0571] (k) a bispecific antibody (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0572] (l) a bispecific antibody (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154;

[0573] (m) a bispecific antibody (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153;

[0574] (n) a bispecific antibody (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154;

[0575] (o) a bispecific antibody (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155;

[0576] (p) a bispecific antibody (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 135, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 145, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 156;

[0577] (q) a bispecific antibody (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155;

[0578] (r) a bispecific antibody (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 146, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 157;

[0579] (s) a bispecific antibody (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 147, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 158;

[0580] (t) a bispecific antibody (QH07 / QL33 / / JH11 / JL11) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 125, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 137, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 148, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 159;

[0581] (u) A bispecific antibody that binds to the same epitope as the epitope in FIX and / or FIXa and the epitope in FX recognized by any one of the antibodies in (a) to (t).

[0582] (v) A multispecific antigen-binding molecule that competitively binds to an epitope in FIX and / or FIXa and an epitope in FX recognized by any one of the antibodies in (a) to (t).

[0583] In one embodiment, the present invention further provides a multispecific antigen-binding molecule having the function of replacing the function of coagulation factor VIII, comprising a first antigen-binding site that binds to coagulation factor IX and / or activated coagulation factor IX, and a second antigen-binding site that binds to coagulation factor X,

[0584] wherein the first antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0585] wherein the heavy chain variable domain (Q499) comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3,

[0586] wherein the light chain variable domain (QNK131) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 162, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 163, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 164, and

[0587] wherein the second antigen binding site comprises a heavy chain variable domain and a light chain variable domain,

[0588] wherein the heavy chain variable domain (J327) comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 4, an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 5, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 6,

[0589] wherein the light chain variable domain (JNL095) comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO:165, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:166, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:167.

[0590] In certain embodiments, the antibodies of (a) to (v) above are antibodies having a function of replacing the function of FVIII.

[0591] In other embodiments, the antibodies of (a) to (v) above are antibodies with reduced reactivity to ACE910 (Emicizumab) idiotype antibodies compared to ACE910 (Emicizumab). In this article, the phrase "compared to ACE910 (Emicizumab), the reactivity to ACE910 (Emicizumab) idiotype antibodies is reduced" means that when the binding strength (%) between the anti-idiotype antibody and the labeled ACE910 is measured using the method described herein, and if the test substance is added at a concentration of 100 μg / mL, the reactivity is preferably reduced by 10% or more, more preferably by 20% or more, and still more preferably by 30% or more.

[0592] Anti-ACE910 (Amicizumab) idiotype antibody can be obtained by, for example, the following method. The F (ab') 2 of Q499 / L404 identifying FIX (a) and the F (ab') 2 of J327 / L404 identifying FX are applied to rabbits to obtain anti-Q499 / L404 F (ab') 2 rabbit serum and anti-J327 / L404 F (ab') 2 rabbit serum. The ammonium sulfate fractions of these serums are added to the column to remove human IgG reactive antibodies. Next, affinity purification is performed using Q499 / L404 (J327 / L404) binding column, and J327 / L404 (Q499 / L404) binding column is used to remove J327 / L404 (Q499 / L404) reactive antibodies, and thus polyclonal anti-idiotype antibodies specifically binding to Q499 / L404 (J327 / L404) are obtained.

[0593] The binding strength (%) of anti-idiotypic antibodies to the ACE910 (Emicizumab) of labeling can be measured by, for example, electrochemiluminescence immunoassay, and this can evaluate the binding inhibition by test substance.When using the anti-idiotypic antibodies obtained as described above, the test substance (bispecific antibody) with a concentration of 0,1,3,10,30 or 100 μg / mL is added to anti-Q499 / L404 idiotypic antibodies, anti-J327 / L404 idiotypic antibodies, biotin-labeled ACE910 (Emicizumab), and the mixture of ACE910 (Emicizumab) labeled by SULFO-TAG, and the resulting mixed solution is incubated overnight under refrigeration.Then, the mixed solution is added to 96-well plates, and the place is washed, and then the binding strength is determined by electrochemiluminescence.

[0594] In other embodiments, the antibodies of (a) to (v) above have enhanced FVIII cofactor function replacement activity and higher activity at low antibody concentrations compared to ACE910 (emicizumab).

[0595] In other embodiments, compared with ACE910 (Amicizumab), the antibodies of (a) to (v) above have substantially no FIX activation inhibitory activity and have increased FVIII cofactor function replacement activity. In this article, the phrase "substantially no FIX activation inhibitory activity" means that when the OD value is measured using the method shown in this specification, the decrease in OD value compared to the control OD value is 0.025 or less, preferably 0.02 or less, more preferably 0.01 or less.

[0596] The amino acids contained in the amino acid sequences described herein may be post-translationally modified (e.g., modification of N-terminal glutamine to pyroglutamic acid by pyroglutamylation is well known to those skilled in the art). Naturally, such sequences with post-translationally modified amino acids are also included in the amino acid sequences described herein.

[0597] On the other hand, the present invention provides multispecific antigen-binding molecules or bispecific antibodies that bind to the same epitope as the multispecific antigen-binding molecules or bispecific antibodies provided herein that bind to FIX and / or FIXa, and FX. For example, in certain embodiments, multispecific antigen-binding molecules or bispecific antibodies are provided that bind to the same epitope as the multispecific antigen-binding molecules or bispecific antibodies described in (a) to (t) above.

[0598] In another aspect of the invention, the bispecific antibody combined with FIX and / or FIXa and FX according to any of the above embodiments is a monoclonal antibody, including a chimeric antibody, a humanized antibody or a human antibody. In one embodiment, the bispecific antibody combined with FIX and / or FIXa, and FX is an antibody fragment, such as (scFv)2, a diabody or a F(ab')2 fragment. In another embodiment, the antibody is a full-length antibody, such as a complete IgG4 antibody or other antibody classes or isotypes defined herein.

[0599] In another aspect, the bispecific antibody that binds to FIX and / or FIXa and FX according to any of the above embodiments may incorporate any of the features, alone or in combination, as described in Sections 1-7 below:

[0600] 1. Antibody affinity

[0601] In certain embodiments, the antibodies provided herein have a molecular weight of 100 μM or less, 10 μM or less, 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or less, or 0.001 nM or less (e.g., 10 -5 M or smaller, e.g. 10 -5 M to 10 -10M, for example 10 -6 M to 10 -10 The dissociation constant (Kd) of the

[0602] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA). In one embodiment, an RIA is performed with a Fab form of the antibody of interest and its antigen. For example, the solution binding affinity of the Fab for the antigen is measured by: in the presence of a titration series of unlabeled antigen, using a minimal concentration of ( 125 I) labeled antigen equilibrated Fab, and then the bound antigen was captured with an anti-Fab antibody coated plate (see, e.g., Chen et al., J. Mol. Biol. 293: 865-881 (1999)). To establish the assay conditions, MICROTITER (registered trademark) multiwell plates (Thermo Scientific) were coated overnight with 5 μg / ml of capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and then blocked with 2% (w / v) bovine serum albumin in PBS at room temperature (about 23°C) for 2 to 5 hours. In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125 I] - Antigen is mixed with serial dilutions of the target Fab (e.g., consistent with the evaluation of anti-VEGF antibody Fab-12 in Presta et al., Cancer Res. 57:4593-4599 (1997)). The target Fab is then incubated overnight; however, the incubation can be continued for a longer time (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixture is transferred to a capture plate and incubated at room temperature (e.g., 1 hour). The solution is then removed and the plate is washed 8 times with 0.1% polysorbate 20 (TWEEN-20 (registered trademark)) in PBS. When the plate is dry, 150 μl / well of scintillant (MICROSCINT-20 TM ; Packard) and the plates were counted for 10 minutes on a TOPCOUNT™ gamma counter (Packard). The concentration of each Fab that produced less than or equal to 20% of maximal binding was selected for competitive binding assays.

[0603] According to another embodiment, Kd is measured using BIACORE (registered trademark) surface plasmon resonance assay. For example, the determination using BIACORE (registered trademark) -2000 or BIACORE (registered trademark) -3000 (BIAcore, Inc., Piscataway, NJ) is carried out with an immobilized antigen CM5 chip at about 10 response units (RU) at 25°C. In one embodiment, according to the supplier's instructions, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The antigen is diluted to 5 μg / mL (~0.2 μM) with 10 mM sodium acetate at pH 4.8 and then injected at a flow rate of 5 μL / min to obtain about 10 response units (RU) of the coupled protein. After the antigen is injected, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, Fabs were cultured in a 4% PBS solution containing 0.05% polysorbate 20 (TWEEN-20 TM Two-fold serial dilutions (0.78 nM to 500 nM) of the surfactant in PBS (PBST) were injected at a flow rate of approximately 25 μL / min at 25°C. The association rate (k) was calculated by simultaneously fitting the association and dissociation sensorgrams using a simple one-to-one Langmuir binding model (BIACORE (registered trademark) Evaluation Software Version 3.2). on ) and dissociation rate (k off The equilibrium dissociation constant (Kd) was calculated as the ratio k off / k on See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate measured by the surface plasmon resonance assay exceeds 10 6 M -1 s -1 , the binding rate can then be determined by using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25°C in the presence of increasing concentrations of antigen as measured in a spectrometer such as a stopped-flow spectrophotometer (Aviv Instruments) or a 8000 series SLM-AMINCO with a stirred cuvette. TM Spectrophotometer (ThermoSpectronic).

[0604] 2. Antibody fragments

[0605] In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, (scFv)2, diabodies or F(ab')2, and other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, for example, Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.

[0606] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).

[0607] As described herein, antibody fragments can be prepared by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (eg, E. coli or bacteriophage).

[0608] 3. Chimeric and humanized antibodies

[0609] In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In another example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0610] In certain embodiments, chimeric antibodies are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to people while retaining the specificity and affinity of the parent non-human antibodies. Typically, humanized antibodies include one or more variable domains, wherein HVR (e.g., CDR) (or a portion thereof) is derived from non-human antibodies, and FR (or a portion thereof) is derived from human antibody sequences. Humanized antibodies optionally also include at least a portion of human constant regions. In some embodiments, some FR residues in humanized antibodies are replaced by corresponding residues from non-human antibodies (e.g., antibodies from which HVR residues are derived), for example, to restore or improve antibody specificity or affinity.

[0611] Humanized antibodies and methods for their preparation are reviewed in, for example, Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in, for example, Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) transplantation); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the "guided selection" method of FR shuffling)).

[0612] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best fit" method (see, e.g., Sims et al., J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1994)). 93)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)).

[0613] 4. Human Antibodies

[0614] In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be generated using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20: 450-459 (2008).

[0615] Human antibodies can be prepared by administering immunogens to transgenic animals that have been modified to produce complete human antibodies or complete antibodies with human variable regions in response to antigenic challenges. Such animals typically contain all or part of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or they exist extrachromosomally or are randomly integrated into the chromosomes of the animal. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, for example, U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE TMThe human variable regions of intact antibodies generated by such animals can be further modified, for example, by combining with different human constant regions.

[0616] Human antibodies can also be generated by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991)). Human antibodies generated via human B cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Other methods include those described in, for example, U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26 (4): 265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20 (3): 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27 (3): 185-91 (2005).

[0617] It is also possible to generate human antibodies by separating the Fv clone variable domain sequences selected from the phage display library derived from humans. Then, such variable domain sequences can be combined with desired human constant domains. The technology of selecting human antibodies from antibody libraries is described below.

[0618] 5. Library-derived Antibodies

[0619] The antibodies of the present invention can be isolated by screening combinatorial libraries to obtain antibodies with one or more desired activities. For example, a variety of methods for generating phage display libraries and screening such libraries to obtain antibodies with desired binding characteristics are known in the art. Such methods are reviewed in, for example, Hoogenboom et al., in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described in, for example, McCafferty et al., Nature 348: 552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology 248: 161-175 (Lo, ed., Human Press, Totowa, NJ, 2001). Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).

[0620] In certain phage display methods, repertoires of VH and VL genes are cloned separately by polymerase chain reaction (PCR) and randomly recombined in phage libraries, which can then be screened for antigen-binding phage, as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994). Phage typically display antibody fragments as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans) to provide a single source of antibodies against a wide range of non-self and self antigens without any immunization, as described by Griffiths et al., EMBO J, 12: 725-734 (1993). Finally, naive libraries can also be prepared synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol., 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373 and U.S. Patent Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936 and 2009 / 0002360.

[0621] Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

[0622] 6. Multispecific Antibodies

[0623] In the context of the present invention, the term "multispecific antibody" refers to an antibody that can specifically bind to different types of epitopes. More specifically, a multispecific antibody is an antibody that is specific to at least two different types of epitopes, and in addition to antibodies that recognize different antigens, it also includes antibodies that recognize different epitopes on the same antigen. (For example, when the antigen is a heterologous receptor, the multispecific antibody binds to the different domains that constitute the heterologous receptor; or, when the antigen is a monomer, the multispecific antibody binds to multiple sites on the monomeric antigen). Typically, such molecules bind to two antigens (bispecific antibodies), but they can even have specificity for more antigens (e.g., three types). In a specific embodiment, one antigen is FIX and / or FIXa, and the other is FX. Bispecific antibodies can be prepared as whole antibodies or antibody fragments.

[0624] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305:537 (1983); WO 93 / 08829; and Traunecker et al., EMBO J. 10:3655 (1991)), and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be prepared by the following methods: engineering electrostatic steering effects to prepare antibody Fc-heterodimer molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229:81 (1985)); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology for preparing bispecific Antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and the use of single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and the preparation of trispecific antibodies, e.g., as described in Tutt et al., J. Immunol. 14760 (1991).

[0625] Engineered antibodies with three or more functional antigen binding sites, including "octopus antibodies," are also included herein (see, e.g., US 2006 / 0025576 A1).

[0626] 7. Antibody variants

[0627] In certain embodiments, it is contemplated that the amino acid sequence variants of the antibodies provided herein. For example, it may be necessary to improve the binding affinity and / or other biological properties of the antibody. The amino acid sequence variants of the antibody can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, the deletion of residues in the amino acid sequence of the antibody, and / or insertion and / or substitution. Any combination of deletion, insertion and substitution can be performed to obtain the final construct, provided that the final construct has the desired characteristics, such as antigen binding.

[0628] a) Substitution, insertion and deletion variants

[0629] In certain embodiments, antibody variants with one or more amino acid substitutions are provided. The target sites for substitution mutagenesis include HVR and FR. Conservative substitutions are shown under the heading of "preferred substitutions" in Table 1. More substantial changes are provided under the heading of "exemplary substitutions" in Table 1, and as further described below with respect to amino acid side chain categories. Amino acid substitutions can be introduced into the target antibody, and the product can be screened for desired activity (e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC).

[0630] [Table 1]

[0631]

[0632] Based on common side chain properties, amino acids can be grouped as follows:

[0633] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;

[0634] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;

[0635] (3) Acidic: Asp, Glu;

[0636] (4) Basic: His, Lys, Arg;

[0637] (5) Residues that affect chain orientation: Gly, Pro;

[0638] (6) Aromatic: Trp, Tyr, Phe.

[0639] Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.

[0640] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., humanized or human antibody). Typically, the resulting variant selected for further study will have certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody (e.g., modification (e.g., improvement) and / or will substantially retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity-matured antibodies that can be easily generated, for example, using affinity maturation techniques based on phage display, such as those described herein. In short, mutate one or more HVR residues and display variant antibodies on phage and screen for specific biological activities (e.g., binding affinity).

[0641] Changes (e.g., substitutions) can be made in HVR, for example, to improve antibody affinity. Such changes can be made in HVR "hot spots" (i.e., residues encoded by codons that undergo high-frequency mutations during somatic maturation) (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)), and / or residues that contact antigens, and the resulting variant VH or VL binding affinity is tested. Affinity maturation by constructing a secondary library and reselecting therefrom has been described, for example, in Hoogenboom et al., in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable gene selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variant with the desired affinity. Another method to introduce diversity involves an HVR-directed approach in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0642] In certain embodiments, substitutions, insertions or deletions may occur within one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody to bind to antigens. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. For example, such changes may be outside the antigen contact residues in HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR is either unchanged or contains no more than one, two or three amino acid substitutions.

[0643] A useful method for identifying residues or regions of an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, residues or groups of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody and antigen is affected. Further substitutions can be introduced at amino acid positions that demonstrate functional sensitivity to the initial substitutions. Alternatively, or in addition, the crystal structure of the antigen-antibody complex can be analyzed to identify contact points between the antibody and the antigen. Such contact residues and neighboring residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain the desired properties.

[0644] Amino acid sequence insertion includes amino and / or carboxyl terminal fusions ranging in length from 1 residue to polypeptides containing 100 or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with N-terminal methionyl residues. Other insertion variants of antibody molecules include fusions of enzymes (e.g., for ADEPT) or polypeptides to the N or C-terminals of antibodies that increase the plasma half-life of antibodies.

[0645] b) Glycosylation variants

[0646] In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent of antibody glycosylation.Adding or deleting glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence to create or remove one or more glycosylation sites.

[0647] When antibody comprises Fc district, can change the carbohydrate connected thereto.Natural antibodies produced by mammalian cells usually comprise branched, two-antenna oligosaccharides, which are usually connected to the Asn297 of the CH2 domain of the Fc district by N connection.See, for example, Wright et al., TIBTECH 15:26-32 (1997).Oligosaccharides can include various carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and the fucose of the GlcNAc in the "stem" of the two-antenna oligosaccharide structure.In some embodiments, the oligosaccharides in the antibody of the present invention can be modified to create antibody variants with some improved characteristics.

[0648] c) Fc region variants

[0649] In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. An Fc region variant can be included in a human Fc region sequence (e.g., human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., substitution) at one or more amino acid positions.

[0650] In certain embodiments, the present invention contemplates antibody variants having some, but not all, effector functions that make them desirable candidates for applications where the in vivo half-life of the antibody is important, while certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / loss of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and therefore likely lacks ADCC activity), but retains FcRn binding ability. NK cells, the main cells used to mediate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-492 (1991). Non-limiting examples of in vitro assays for evaluating ADCC activity of target molecules are described in U.S. Pat. Nos. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry). TMNon-radioactive cytotoxicity assays (Cell Technology, Inc. Mountain View, CA; and CytoTox 96 (registered trademark) non-radioactive cytotoxicity assays (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or in addition, ADCC activity of the target molecule can be assessed in vivo, for example, in an animal model (such as disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA 95:652-656 (1998)). C1q binding assays can also be performed to confirm that the antibody cannot bind to C1q and therefore lacks CDC activity. See, for example, WO 2006 / 029879 and WO 2005 / 100402 C1q and C3c binding ELISA. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103: 2738-2743 (2004)). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18 (12): 1759-1769 (2006)).

[0651] Certain antibody variants with increased or decreased binding to FcRs have been described (see, eg, US Pat. No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001)).

[0652] Antibodies with increased half-life and increased binding to the neonatal Fc receptor (FcRn) are described in US 2005 / 0014934A1 (Hinton et al.), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). Those antibodies comprise an Fc region having one or more substitutions therein that increase binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more of the following Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434, e.g., substitution of Fc region residue 434 ( U.S. Pat. No. 7,371,826 ).

[0653] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351 (which concerns other examples of Fc region variants).

[0654] d) Cysteine ​​engineered antibody variants

[0655] In certain embodiments, it may be desirable to produce cysteine ​​engineered antibodies, such as "thioMAbs," in which one or more residues of an antibody are substituted with cysteine ​​residues. In a specific embodiment, the substituted residues appear at accessible sites of the antibody. By replacing those residues with cysteine, reactive thiol groups are thus positioned at accessible sites of the antibody and can be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to produce immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine ​​engineered antibodies can be generated as described, for example, in U.S. Patent No. 7,521,541.

[0656] e) Antibody derivatives

[0657] In certain embodiments, the antibodies provided herein can be further modified to contain additional nonproteinaceous parts known in the art and easily available. Suitable parts for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly-(n-vinyl pyrrolidone) polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol and mixtures thereof. Polyethylene glycol propionaldehyde has advantages in manufacturing due to its stability in water. The polymer can be any molecular weight, and can be branched or unbranched. The number of polymers connected to the antibody can vary, and if more than one polymer is connected, they can be the same or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the specific property or function of the antibody to be improved, whether the antibody derivative will be used therapeutically under defined conditions, etc.

[0658] In another embodiment, a conjugate of an antibody and a non-protein moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, and includes, but is not limited to, a wavelength that does not damage normal cells but can heat the non-protein moiety to a temperature that kills cells that are close to the antibody-non-protein moiety.

[0659] B. Recombinant Methods and Compositions

[0660] Recombinant methods and compositions can be used to produce antibodies, for example, as described in U.S. Patent No. 4,816,567. In one embodiment, there is provided an isolated nucleic acid encoding a multispecific antibody that binds to FIX and / or FIXa and FX as described herein. Such nucleic acids can encode an amino acid sequence comprising the VL of the antibody and / or an amino acid sequence comprising the VH of the antibody (e.g., a light chain and / or a heavy chain of the antibody). In a further embodiment, one or more vectors (e.g., an expression vector) comprising such nucleic acids are provided. In a further embodiment, a host cell comprising such nucleic acids is provided. In one such embodiment, the host cell comprises (e.g., has been transformed with the following vectors): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector and a second vector, wherein the first vector comprises a nucleic acid encoding an amino acid sequence comprising the VL of the antibody, and the second vector comprises a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, Sp2 / 0 cell). In one embodiment, a method for preparing a multispecific antibody that binds to FIX and / or FIXa and FX is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding an antibody as provided above under conditions suitable for expressing a multispecific antibody that binds to FIX and / or FIXa and FX, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0661] For the recombinant production of multispecific antibodies that bind to FIX and / or FIXa and FX, nucleic acids encoding the antibodies are isolated (e.g., as described above) and inserted into one or more vectors for further cloning and / or expression in a host. Such nucleic acids can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of specifically binding to genes encoding the heavy and light chains of the antibodies).

[0662] Suitable host cells for cloning or expressing antibody encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199 and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in Escherichia coli). After expression, antibodies can be separated from bacterial cell paste in the soluble fraction and can be further purified.

[0663] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized" to produce antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004); and Li et al., Nat. Biotech. 24: 210-215 (2006).

[0664] Host cells suitable for expressing glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used with insect cells, particularly for transfecting Spodoptera frugiperda cells.

[0665] Plant cell cultures can also be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe PLANTIBODIES for producing antibodies in transgenic plants). TM technology).

[0666] Vertebrate cells can also be used as hosts. For example, mammalian cell lines suitable for suspension growth can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 lines (COS-7) transformed by SV40; human embryonic kidney cell lines (293 or 293 cells, such as described in, for example, Graham et al., J. Gen Virol. 36: 59 (1977)); baby hamster kidney cells (BHK); mouse supporting cells (sertoli cells) (TM4 cells, such as described in, for example, Mather, Biol. Reprod. 23: 243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (HepG2); mouse mammary tumor (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, which include DHFR - CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines, such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0667] C. Determination

[0668] The multispecific antigen-binding molecules provided herein that bind to FIX and / or FIXa and FX can be identified, screened or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.

[0669] 1. Binding Assays and Other Assays

[0670] In one aspect, the antigen binding activity of the antibodies of the invention is tested, for example, by known methods such as ELISA, Western blot, and the like.

[0671] On the other hand, competition assays can be used to identify antibodies that compete with any multispecific antibody in combination with FIX and / or FIXa and FX as described herein for binding to FIX and / or FIXa and FX. In certain embodiments, such competitive antibodies bind to the same epitope (e.g., linear or conformational epitopes) as the multispecific antibodies in combination with FIX and / or FIXa and FX as described herein. Detailed exemplary methods for drawing epitopes that antibodies bind to are provided in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).

[0672] In an exemplary competitive assay, immobilized FIX, FIXa or FX is incubated in a solution comprising a first labeled antibody (e.g., any antibody described herein) that binds FIX, FIXa or FX and a second unlabeled antibody that is testing its ability to compete with the first antibody to bind FIX, FIXa or FX. The second antibody may be present in a hybridoma supernatant. As a control, immobilized FIX, FIXa or FX is incubated in a solution comprising the first labeled antibody but not comprising the second unlabeled antibody. After incubation under conditions that allow the first antibody to bind to FIX, FIXa or FX, excess unbound antibody is removed, and the amount of the labeling combined with immobilized FIX, FIXa or FX is measured. If the amount of the labeling combined with immobilized FIX, FIXa or FX in the test sample is substantially reduced relative to the control sample, it is shown that the second antibody competes with the first antibody to bind FIX, FIXa or FX. Referring to Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0673] 2. Activity Assay

[0674] In one aspect, an assay for identifying the biological activity of a multispecific antigen-binding molecule that binds to FIX and / or FIXa and FX and has biological activity is provided. The biological activity may include, for example, an activity that promotes the generation of FXa. Also provided are multispecific antigen-binding molecules that have such biological activity in vivo and / or in vitro.

[0675] In certain embodiments, such biological activities of the antibodies of the invention are tested. "FVIII cofactor function replacement activity" means, for example, the activity of increasing absorbance in a test of the FX activation reaction by FIXa using a colorimetric quantitative method, and the activity of increasing the amount of thrombin generated calculated in a thrombin generation test using hemophilia A serum.

[0676] Using colorimetric quantification, FVIII cofactor function replacement activity can be evaluated, specifically, by evaluating it in a measurement system comprising a multispecific antigen binding molecule of the present invention and, for example, FIXa, FX, a synthetic substrate S-2222 (a synthetic substrate for FXa) and a phospholipid. For example, it can be measured by the following method. All reactions are carried out at room temperature. 5 μL of antibody solution diluted with Tris-buffered saline (hereinafter referred to as TBSB) containing 0.1% bovine serum albumin is mixed with 5 μL of 150 ng / mL human factor IXaβ (Enzyme Research Laboratories), which is then incubated at room temperature for 30 minutes in a 384-well plate. The enzyme reaction in the mixture is initiated by adding 5 μL of 24.7 μg / mL human factor X (Enzyme Research Laboratories), and after 4 minutes, 5 μL of 0.5M EDTA is added to terminate the reaction. The color reaction is initiated by adding 5 μL of chromogenic substrate solution. After 30 minutes of color development reaction, SpectraMax 340PC384 (Molecular Devices) was used to measure the absorbance change at 405nm. The solvent of human factor IXaβ and human factor X is TBSB containing 4.0μM phospholipid solution (SYSMEX CO.) and 1.5mM CaCl2. S-2222 (SEKISUI MEDICAL) is dissolved in purified water to provide a chromogenic substrate solution of 1.47mg / mL, and is used for this determination. The measurement system shows the correlation with the severity of the disease and clinical symptoms in hemophilia A cases (Rosen S, Andersson M, Blomback M et al., Clinical applications of achromogenic substrate method for determination of FVIII activity. Thromb Haemost 1985; 54: 811-23).

[0677] Using the thrombin generation test, the FVIII cofactor function replacement activity can be evaluated, specifically, by using a measurement system comprising a multispecific antigen binding molecule of the present invention and, for example, FVIII-deficient plasma, activated coagulation factor XI, phospholipids, a fluorescent buffer (Fluo-buffer) and a fluorescent substrate (Fluo-Substrate) (FluCa-Kit; a synthetic substrate for thrombin). For example, it can be measured by the following method. 8 μL of bispecific antibodies diluted with TBSB are added to 72 μL of FVIII-deficient plasma (George King) and incubated at room temperature for 30 minutes or longer. Subsequently, 20 μL of a trigger solution containing 20 μM phospholipids and 5 ng / mL human factor XIa (Enzyme Research Laboratories) is added. Then, a mixed solution of a fluorescent buffer and a fluorescent substrate of 20 μL FluCa-Kit (Thrombinoscope) is added to initiate a coagulation reaction. The amount of thrombin generation can be assessed using a thrombin generation fluorescence measurement and analysis system (Thrombinoscope). Thrombin generation tests using hemophilia A plasma show general coagulation activity in hemophilia A cases and correlate with clinical symptoms of the disease (Shima M, Matsumoto T & Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14: 83-92).

[0678] The term "FIX activation inhibition activity" refers to the use of colorimetric quantitative method by FXIa FIX activation reaction absorbance reduction. Specifically, the following method is carried out. 5 μL antibody solution diluted with TBSB is mixed with 5 μL 3U / mL human factor IX (Christmassin M, Japan Blood Products Agency), and then incubated at room temperature for 30 minutes in 384 well plates. The enzyme reaction in the mixture is initiated by adding 5 μL 90ng / mL human factor XIa (Enzyme Research Laboratory), and after 60 minutes, it is terminated by adding 5 μL 0.5M EDTA. The color reaction is initiated by adding 10 μL chromogenic substrate solution. After 60 minutes of color reaction, the absorbance change at 405nm is measured using SpectraMax 340PC384 (Molecular Devices). The solvent of human factor IX and human factor XIa is TBSB containing 6.0 μM phospholipid solution (SYSMEX CO.) and 1.5mM CaCl2. Spectrozyme FIXa (Sekisui Diagnostics) was dissolved in purified water to provide a 6.7 mM chromogenic substrate solution, and this was mixed with ethylene glycol at 5:8 and used in this assay.

[0679] Referring to US2014 / 0080153 (WO 2012 / 093704), the binding of antibodies to ECM (extracellular matrix) can be evaluated by the following procedure. ECM-free phenol red (BD Matrigel #6137013) was diluted with 2 mg / mL TBS, and 5ul of this dilution was dropped into the center of each well of the plate for ECL measurement (L15XB-6, MSD high binding), cooled on ice. Then, it was sealed with a plate seal and placed at 4°C overnight. Next, the antibody sample was diluted to 9 μg / mL with ACES-T (20mMACES, 150mM NaCl, pH 7.4 or pH 5.8, supplemented with 0.01% Tween 20). The secondary antibody was diluted to 2 μg / mL with ECLDB (ACES supplemented with 0.1% BSA and 0.01% Tween20). 25 μL of antibody solution was added to a round bottom plate, and 50 μL of ECLDB was equally divided in each well. The ECL blocking buffer was removed by tilting from the ECM plate containing ECL blocking buffer, and then 50 μL of each of the above antibody solutions was added to the plate. Then, it was stirred at room temperature for one hour. After removing the sample by tilting, 50 μL of 0.25% glutaraldehyde (prepared with ACES-T) was added to each well and placed at room temperature for 10 minutes. Each well was washed 3 times with PBS-T (PBS supplemented with 0.05% Tween 20), and 50 μL of secondary antibody diluted to 1 μg / mL with ECLDB was added to each well, and it was stirred at room temperature for 1 hour in the dark. Then, 150 μL of READ buffer (MSD) was added to each well, and the luminescent signal using sulfonyl tag was detected using MESO SECTOR S600 (Meso Scale Discovery).

[0680] F. Pharmaceutical preparations

[0681] Pharmaceutical formulations of multispecific antigen-binding molecules that bind to FIX and / or FIXa and FX as described herein are prepared by mixing such multispecific antigen-binding molecules of the desired purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)) (in the form of a lyophilized formulation or an aqueous solution). Pharmaceutically acceptable carriers are generally nontoxic to receptors at the doses and concentrations employed, and include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) () polypeptide; protein, such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymer, such as polyvinyl pyrrolidone; amino acid, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharide, disaccharide and other carbohydrate, including glucose, mannose or dextrin; chelating agent, such as EDTA; sugar, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterion, such as sodium; metal complex (such as zinc protein complex); and / or nonionic surfactant, such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersants, such as soluble neutral-active hyaluronidase glycoprotein (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENE (registered trademark), Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0682] Exemplary lyophilized antibody formulations are described in US Pat. No. 6,267,958. Aqueous antibody formulations include those described in US Pat. No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.

[0683] The preparations herein may also contain more than one active ingredient, which is necessary for the specific indications treated, preferably those with complementary activities but which do not adversely affect each other. For example, it may be necessary to further provide FVIII, FVII, FIX, TFPI inhibitors, siRNA targeting antithrombin; more specifically, Advate, Adynovate, Feiba, NovoSeven, NovoEight, N8-GP, N9-GP, Concizumab, Elocta and Fitusiran. Such active ingredients are appropriately present in an effective amount combination for the intended purpose. FVIII, FVII and FIX may include their Fc fusions and PEG fusions.

[0684] The active ingredient can be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0685] Sustained release preparations can be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the multispecific antigen-binding molecules, which matrices are in the form of shaped articles, eg films, or microcapsules.

[0686] Formulations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.

[0687] G. Methods of Treatment and Compositions

[0688] Any of the multispecific antigen-binding molecules provided herein that bind to FIX and / or FIXa and FX can be used in therapeutic methods.

[0689] On the one hand, a multispecific antigen binding molecule is provided that is combined with FIX and / or FIXa and FX, which is used as a medicine. On the other hand, a multispecific antigen binding molecule is provided that is combined with FIX and / or FIXa and FX for treating bleeding, a disease involving bleeding or a disease caused by bleeding. In certain embodiments, a multispecific antigen binding molecule that is combined with FIX and / or FIXa and FX is provided for treating a method. In certain embodiments, the present invention provides a multispecific antigen binding molecule that is combined with FIX and / or FIXa and FX, for treating an individual with bleeding, a disease involving bleeding or a disease caused by bleeding, comprising administering to an individual an effective amount of a multispecific antigen binding molecule that is combined with FIX and / or FIXa and FX. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, such as described below. In a further embodiment, the present invention provides a multispecific antigen binding molecule that is combined with FIX and / or FIXa and FX, for replacing the FVIII cofactor function. In certain embodiments, the present invention provides a multispecific antigen binding molecule that binds to FIX and / or FIXa and FX, a method for replacing the FVIII cofactor function in an individual, comprising administering to the individual an effective multispecific antigen binding molecule that binds to FIX and / or FIXa and FX to replace the FVIII cofactor function. According to any one of the above embodiments, the "individual" is preferably a human. In the present invention, "hemorrhage, a disease involving bleeding or a disease caused by bleeding" is preferably a disease that is formed and / or progresses due to a decrease or lack of activity of FVIII and / or activated coagulation factor VIII (FVIIIa). Such diseases include the above-mentioned hemophilia A, hemophilia B, hemophilia C, diseases in which inhibitors to FVIII / FVIIIa appear, acquired hemophilia and von Willebrand disease, but are not particularly limited thereto.

[0690] In another aspect, the present invention provides the use of a multispecific antigen binding molecule that binds to FIX and / or FIXa and FX in the manufacture or preparation of a drug. In one embodiment, the drug is used to treat bleeding, a disease involving bleeding, or a disease caused by bleeding. In a further embodiment, the drug is used to treat a method for treating bleeding, a disease involving bleeding, or a disease caused by bleeding, comprising administering an effective amount of the drug to an individual with bleeding, a disease involving bleeding, or a disease caused by bleeding. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual, such as described below. In a further embodiment, the drug is used to replace the FVIII cofactor function. In a further embodiment, the drug is used to replace the FVIII cofactor function in an individual, comprising administering an effective amount of the drug to the individual to replace the FVIII cofactor function. According to any one of the above embodiments, the "individual" can be a human. In the present invention, "bleeding, a disease involving bleeding, or a disease caused by bleeding" is preferably a disease that is formed and / or progresses due to a decrease or lack of activity of FVIII and / or FVIIIa. Such diseases include the above-mentioned hemophilia A, hemophilia B, hemophilia C, diseases in which inhibitors to FVIII / FVIIIa appear, acquired hemophilia and von Willebrand disease, but are not particularly limited thereto.

[0691] On the other hand, the present invention provides a method for treating hemorrhage, a disease related to hemorrhage or a disease caused by hemorrhage. In one embodiment, the method includes administering an effective amount of a multispecific antigen binding molecule combined with FIX and / or FIXa and FX to an individual with hemorrhage, a disease related to hemorrhage or a disease caused by hemorrhage. In one such embodiment, the method further includes administering an effective amount of at least one other therapeutic agent to the individual, as described below. According to any one of the above embodiments, "individual" can be a person.

[0692] In another aspect, the invention provides a method for replacing FVIII cofactor function in an individual. In one embodiment, the method comprises administering to the individual an effective amount of a multispecific antigen binding molecule that binds to FIX and / or FIXa and FX to replace FVIII cofactor function. In one embodiment, the "individual" is a human.

[0693] On the other hand, the present invention provides a pharmaceutical preparation comprising any multispecific antigen-binding molecule combined with FIX and / or FIXa and FX as provided herein, for example, for any of the above methods of treatment. In one embodiment, the pharmaceutical preparation comprises any multispecific antigen-binding molecule combined with FIX and / or FIXa and FX as provided herein and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical preparation comprises any multispecific antigen-binding molecule combined with FIX and / or FIXa and FX as provided herein and at least one additional therapeutic agent, for example, as described below.

[0694] The multispecific antigen binding molecules of the present invention can be used alone or in combination with other agents in treatment. For example, the antibodies of the present invention can be co-administered with at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent is, for example, FVIII, FVII, FIX, TFPI inhibitors, siRNA targeting antithrombin; more specifically, Advate, Adynovate, Feiba, NovoSeven, NovoEight, N8-GP, N9-GP, Concizumab, Elocta and Fitusiran. FVIII, FVII and FIX can be Fc fusions and PEG fusions thereof.

[0695] Such combination therapies mentioned above encompass both co-administration (where two or more therapeutic agents are included in the same or separate formulations) and separate administration, in which case administration of the multispecific antigen-binding molecules of the invention can occur before, simultaneously with, and / or after administration of the additional therapeutic agent or agent. In one embodiment, administration of the multispecific antigen-binding molecule that binds to FIX and / or FIXa and FX, and administration of the additional therapeutic agent occur within about one month, two months, three months, four months, five months, or six months of each other, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days.

[0696] The multispecific antigen-binding molecules of the invention (and any additional therapeutic agents) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Administration can be by any suitable route, for example, by injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is transient or chronic. Various dosing regimens are contemplated herein, including but not limited to single administration or multiple administrations at multiple time points, bolus administration, and pulse infusions.

[0697] The multispecific antigen-binding molecules of the present invention will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to be considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the site of delivery of the agent, the method of administration, the schedule of administration, and other factors known to medical practitioners. The multispecific antigen-binding molecules are not required, but are optionally formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of the multispecific antigen-binding molecule present in the formulation, the type of condition or treatment, and the other factors discussed above. These are generally used in the same dosages and routes of administration as described herein, or at about 1-99% of the dosages described herein, or at any dosage and any route determined empirically / clinically to be appropriate.

[0698] For the prevention or treatment of disease, the appropriate dosage of the multispecific antigen-binding molecules of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of multispecific antigen-binding molecule, the severity and course of the disease, whether the multispecific antigen-binding molecule is administered for preventive or therapeutic purposes, previous treatments, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The multispecific antigen-binding molecules are appropriately administered to the patient once or over a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg-10 mg / kg) of the multispecific antigen-binding molecule can be used as an initial candidate dose for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. Depending on the above factors, a typical daily dose may range from about 1 μg / kg to 100 mg / kg or more. For repeated administration over several days or longer, depending on the condition, treatment will generally continue until the desired suppression of disease symptoms occurs. An exemplary dosage of the multispecific antigen binding molecule will be in the range of about 0.05mg / kg to about 10mg / kg. Therefore, one or more dosages (or any combination thereof) of about 0.5mg / kg, 2.0mg / kg, 4.0mg / kg or 10mg / kg can be administered to the patient. Such dosages can be administered intermittently, for example, weekly or every three weeks (for example, so that the patient receives about two to about twenty, or for example, about six dosages of multispecific antigen binding molecules). An initial higher loading dose can be administered, followed by one or more lower doses. However, other dosage regimens may be useful. It is easy to monitor the progress of the therapy by conventional techniques and assays.

[0699] It will be understood that any of the above formulations or treatment methods can be implemented using an immunoconjugate of the invention instead of or in addition to a multispecific antigen-binding molecule that binds to FIX and / or FIXa and FX.

[0700] H.Products

[0701] In another aspect of the invention, an article of manufacture is provided, which contains materials for treating, preventing and / or diagnosing the above-mentioned conditions. The article of manufacture comprises a container and a label on the container or a package insert associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed of a variety of materials such as glass or plastic. The container holds a composition that is effective for treating, preventing and / or diagnosing a condition, either alone or in combination with another composition, and may have a sterile access port (for example, the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). At least one active ingredient in the composition is a multispecific antigen-binding molecule of the present invention. The label or package insert indicates that the composition is used to treat a selected condition. In addition, the article of manufacture may comprise (a) a first container containing a composition, wherein the composition comprises a multispecific antigen-binding molecule of the present invention; and (b) a second container containing a composition, wherein the composition comprises an additional cytotoxic or other therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the composition can be used to treat a specific condition. Alternatively, or in addition, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles and syringes.

[0702] Another embodiment of the present invention relates to an antigen-binding molecule in which the association of heavy chains and light chains is regulated, a method for producing an antigen-binding molecule in which the association of heavy chains and light chains is regulated, and a method for regulating the association of heavy chains and light chains in an antigen-binding molecule.

[0703] The antigen-binding molecules of the present invention relate to antigen-binding molecules in which the association of heavy chains and light chains is regulated, wherein the heavy chains and light chains constituting the antigen-binding molecules are a combination of target heavy chains and light chains, and wherein the amino acid residues at given positions in the heavy chain constant region (CH1) and the light chain constant region (CL) are amino acid residues that electrically repel each other (have the same charge).

[0704] In the present invention, by making the amino acid residues at given positions in CH1 and CL of an undesirable combination of heavy chains and light chains become amino acid residues that electrostatically repel each other (i.e., have the same charge), by utilizing this charge repulsion, the formation of an undesirable combination of heavy chains and light chains can be prevented, and as a result, a desired combination of heavy chains and light chains can be formed.

[0705] In the present invention, the phrases "regulate the association" and "association is regulated" refer to regulating to achieve desired association conditions, and more specifically to regulating so that undesired associations are not formed between the heavy chain and the light chain.

[0706] In the present invention, the term "interface" generally refers to an association surface generated by association (interaction), and the amino acid residues forming the interface are generally one or more amino acid residues included in the polypeptide region participating in the association, and more preferably amino acid residues that approach each other during the association process and participate in the interaction. More specifically, such interactions include, for example, examples in which amino acid residues approach each other during the association process to form hydrogen bonds, electrostatic interactions or salt bridges.

[0707] In the present invention, the phrase "amino acid residues forming an interface" more specifically refers to the amino acid residues included in the polypeptide region constituting the interface. For example, the polypeptide region constituting the interface refers to the polypeptide region responsible for selective binding between molecules such as antigen-binding molecules (e.g., antibodies), ligands, receptors, or substrates. More specifically, in antigen-binding molecules, such examples include heavy chain constant regions, heavy chain variable regions, light chain constant regions, and light chain variable regions.

[0708] In the present invention, "modification" of amino acid residues specifically refers to replacing the original amino acid residues with other amino acid residues, deleting the original amino acid residues, adding new amino acid residues, etc., but preferably refers to replacing one or more original amino acid residues with other amino acid residues.

[0709] In a preferred embodiment of the antigen-binding molecule of the present invention, the antigen-binding molecule has electrically repulsive (having the same charge) amino acid residues at given positions in CH1 and CL of the undesired combination of heavy and light chains before association regulation.

[0710] By modifying the amino acid residues in the above antigen-binding molecules to amino acid residues that electrostatically repel each other (have the same charge), it is thought that the association of these amino acid residues is suppressed by the charge repulsion.

[0711] Therefore, in the aforementioned antigen-binding molecules, the amino acid residues to be modified are preferably amino acid residues that are close to each other when associated in the polypeptide regions forming the interface.

[0712] The amino acid residues that are in close proximity during association can be determined, for example, by analyzing the three-dimensional structure of the polypeptide and studying the amino acid sequence of the polypeptide region that forms the interface during polypeptide association. Amino acid residues at the interface that are in close proximity to each other are preferred targets for "modification" in the antigen-binding molecules of the present invention.

[0713] It is known that some amino acids are charged. Generally, lysine (K), arginine (R) and histidine (H) are known to be amino acids with a positive charge (positively charged amino acids). Aspartic acid (D), glutamic acid (E) and the like are known to be amino acids with a negative charge (negatively charged amino acids). In addition, alanine (A), asparagine (N), cysteine ​​(C), glutamine (Q), glycine (G), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), valine (V) and the like are known to be amino acids that are not charged, or non-polar amino acids.

[0714] Therefore, in the present invention, amino acids that electrostatically repel each other (having the same charge) refer to:

[0715] (1) amino acids, one of which is a positively charged amino acid and the other is also a positively charged amino acid, and

[0716] (2) Amino acids, one of which is a negatively charged amino acid and the other is also a negatively charged amino acid.

[0717] Amino acids can be modified according to various methods known in the art. Examples of these methods include, but are not limited to, site-directed mutagenesis (Hashimoto-Gotoh, T., Mizuno, T., Ogasahara, Y. and Nakagawa, M. (1995) Anoligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis, Gene 152, 271-275; Zoller, MJ and Smith, M. (1983) Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors, Methods Enzymol. 100, 468-500; Kramer, W., Drutsa, V., Jansen, HW, Kramer, B., Pflugfelder, M. and Fritz, HJ (1984) The gapped duplex DNA approach to oligonucleotide-directed mutation construction, Nucleic Acids Res. 12, 9441-9456; Kramer, W. and Fritz, HJ (1987) Oligonucleotide-directed construction of mutations via gapped duplexDNA, Methods Enzymol. 154, 350-367; Kunkel, TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection, Proc.Natl.Acad.Sci.USA82,488-492), PCR mutagenesis, cassette mutagenesis, etc.

[0718] Examples of amino acid modifications include modifying uncharged amino acids or nonpolar amino acids to positively charged amino acids, modifying uncharged amino acids or nonpolar amino acids to negatively charged amino acids, modifying positively charged amino acids to negatively charged amino acids, and modifying negatively charged amino acids to positively charged amino acids. In addition, modifying uncharged amino acids or nonpolar amino acids to different uncharged or nonpolar amino acids, modifying positively charged amino acids to different positively charged amino acids, and modifying negatively charged amino acids to different negatively charged amino acids are also included in the amino acid modifications of the present invention.

[0719] In the present invention, the modified amino acids include one modification in each heavy chain and light chain, or multiple modifications in each heavy chain and light chain. In addition, the number of modifications added to the heavy chain and light chain can be the same or different.

[0720] In the present invention, the modified amino acids include multiple modifications to positively charged amino acids on the heavy chain or light chain, and multiple modifications to negatively charged amino acids on the other chain. In addition, multiple modifications to positively charged amino acids and multiple modifications to negatively charged amino acids can be performed on the same heavy chain or light chain. Among these modifications, modifications to uncharged amino acids or non-polar amino acids and modifications to uncharged amino acids or non-polar amino acids can also be appropriately combined.

[0721] In the modification of the present invention, for example, amino acids on one chain may be used as they are without modification, and in this case, both the heavy chain and the light chain need not be modified, and only one chain may be modified.

[0722] Although there is no particular restriction on the number of amino acid residues to be modified in the antigen-binding molecules of the present invention, for example, when modifying the constant region of an antibody, in order not to reduce the binding activity to the antigen and in order not to increase the immunogenicity, it is preferred to modify as few amino acid residues as possible. The aforementioned "few" refers to, for example, a number of about 1 to 30, preferably a number of about 1 to 20, even more preferably a number of about 1 to 15, and most preferably a number of 1 to 5.

[0723] The light chain constant region of the antigen binding molecule of the present invention is preferably a human light chain constant region. Examples of antibody light chain constant regions include IgK (κ), IgL1, IgL2, IgL3, IgL6 and IgL7 (λ) type constant regions. The light chain constant region of the antigen binding molecule of the present invention is not particularly limited; when multiple types of light chains are used, the light chains can be different types of light chains, for example, κ and λ. Several allotype sequences obtained by genetic polymorphism are described in "Sequences of Proteins of Immunological Interest, NIH Publication No.91-3242" as human IgK (κ) constant region and human IgL7 (λ) constant region, and any of these can be used in the present invention.

[0724] Antibody constant region, particularly heavy chain constant region, can be modified as needed to improve the function or stability of antigen binding molecules. Examples of modifications for improving the function of antigen binding molecules include modifications that enhance or weaken the binding between antigen binding molecules and Fcγ receptors (FcγR), modifications that enhance or weaken the binding between antigen binding molecules and FcRn, modifications that enhance or weaken the cytotoxic activity (such as ADCC activity and CDC activity) of antigen binding molecules, etc. In addition, modifications that improve the heterogeneity of antigen binding molecules and modifications that improve immunogenicity and / or pharmacokinetics may also be included.

[0725] Furthermore, as heterogeneity of the heavy chain C-terminal sequence of IgG antibodies, amidation of the C-terminal carboxyl group by deleting the C-terminal amino acid, lysine residue, or by deleting two C-terminal amino acids, glycine and lysine, has been reported (Anal. Biochem. 2007 Jan 1:360(1):75-83).

[0726] Therefore, in the present invention, in order to reduce the heterogeneity of the heavy chain C-terminus, it is preferred to use IgG in which the C-terminal lysine or the C-terminal lysine and glycine have been deleted.

[0727] Since their antigenicity is reduced in humans, chimeric and humanized antibodies using human sequences are expected to be useful when administered to humans for therapeutic purposes, etc.

[0728] A preferred example of the antigen-binding molecule of the present invention is a heteromultimer having two or more types of CH1 and two or more types of CL. The heteromultimer preferably binds to two or more types of epitopes, and an example thereof is a multispecific antibody.

[0729] The preferred example of the multispecific antibody of the present invention is a bispecific antibody. Therefore, the example of the preferred embodiment of the antigen binding molecule of the present invention is a bispecific antibody composed of two types of heavy chains (the first heavy chain and the second heavy chain) and two types of light chains (the first light chain and the second light chain).

[0730] More accurately describe the "bispecific antibody" of the preferred embodiment of the antigen-binding molecule of the present invention, the above-mentioned "first heavy chain" refers to one of the two heavy chains (H chains) forming the antibody, and "the second H chain" refers to another H chain different from the first H chain. That is, in two H chains, one of them can be arbitrarily defined as the first H chain, and the other can be defined as the second H chain. Similarly, "the first light chain" refers to one of the two light chains (L chains) forming the bispecific antibody, and "the second L chain" refers to another L chain different from the first L chain. In two L chains, one of them can be arbitrarily defined as the first L chain, and the other can be defined as the second L chain. Generally, the first L chain and the first H chain are derived from the same antibody combined with certain antigens (or epitopes), and the second L chain and the second H chain are also derived from the same antibody combined with certain antigens (or epitopes). In this article, the L chain-H chain pair formed by the first H chain and the L chain is referred to as the first pair, and the L chain-H chain pair formed by the second H chain and the L chain is referred to as the second pair. The antigen (or epitope) for producing the second pair of antibodies derived from is preferably different from the antigen for producing the first pair of antibodies derived from. More specifically, the antigens identified by the first pair and the second pair can be the same, but preferably, the pair is in conjunction with different antigens (or epitopes). In this case, the H chains and L chains of the first pair and the second pair preferably have amino acid sequences different from each other. When the first pair and the second pair are in conjunction with different epitopes, the first pair and the second pair can identify completely different antigens, or they can identify different sites (different epitopes) on the same antigen. In addition, one of them can identify antigens, such as proteins, peptides, genes or sugars, and the other can identify cytotoxic substances, such as radioactive substances, chemotherapeutic agents or cell-derived toxins. However, when it is desired to produce an antibody with a pair formed by a specific combination of H chains and L chains, those specific H chains and L chains can be arbitrarily determined as the first pair and the second pair.

[0731] A more detailed description is provided below regarding an IgG-type bispecific antibody having two types of heavy chain constant regions CH1 (CH1-A and CH1-B) and two types of light chain constant regions (CL-A and CL-B); however, the present invention can also be similarly applied to other antibodies.

[0732] When it is desired to obtain a bispecific antibody that can recognize one epitope through the first CH1-A and the first CL-A and bind to another epitope through the second CH1-B and the second CL-B, when the antibody is produced by expressing each of the four types of chains, theoretically 10 types of antibody molecules may be produced.

[0733] In this case, for example, if the association is regulated to inhibit the association between CH1-A and CL-B and / or CH1-B and CL-A, the desired antibody molecule can be preferentially obtained.

[0734] One example is to modify the amino acid residues forming the interface between CH1-A and CL-B to positively charged amino acid residues, and to modify the amino acid residues forming the interface between CH1-B and CL-A to negatively charged amino acid residues. As a result of these modifications, since the amino acid residues forming the interface are all positively charged, the unexpected association between CH1-A and CL-B is suppressed, and since the amino acid residues forming the interface are all negatively charged, the association between CH1-B and CL-A is also suppressed. Therefore, since the amino acid residues forming the interface have the same charge as each other, the unexpected association between CH1-A and CL-B and the association between CH1-B and CL-A are suppressed. As a result, an antibody having the expected association between CH1-A and CL-A and the expected association between CH1-B and CL-B can be effectively obtained. In addition, since the amino acid residues forming the interface have different types of charges, the expected association between CH1-A and CL-A is promoted, and since the amino acid residues forming the interface have different types of charges, the expected association between CH1-B and CL-B is also promoted. Therefore, antibodies with expected association can be efficiently obtained.

[0735] Another example is when the amino acid residues forming the interface between CL1-A and CL1-B are mutually uncharged or non-polar amino acids, the amino acid residues forming the interface between CH1-A and CL-B are modified to positively charged amino acid residues. As a result of this modification, because the amino acid residues forming the interface are all positively charged, the unexpected association between CH1-A and CL-B is suppressed. On the other hand, since the amino acid residues forming the interface are amino acids that do not electrostatically repel each other, the expected association between CH1-A and CL-A and the expected association between CH1-B and CL-B will be more likely to occur compared to the case of electrostatic repulsion of amino acids. Therefore, antibodies with the expected association between CH1-A and CL-A and the expected association between CH1-B and CL-B can be effectively obtained. At the same time, in this example, in the case where the amino acid residues forming the interface between CL-A and CH1-B are not mutually uncharged or non-polar amino acids, they can be modified to become mutually uncharged or non-polar amino acids.

[0736] Furthermore, in another example, when the amino acid residues forming the interface between CL-B and CH1-B are uncharged or non-polar amino acids in CH1-B, one of the amino acid residues forming the interface between CH1-A and CL-A is modified to a positively charged amino acid residue, and the other is modified to a negatively charged amino acid residue; and the amino acid residues forming the interface between CL-B and CH1-B in CL-B are modified to have the same charge as the modification made to CH1-A. As a result of this modification, although the intended association between CH1-A and CL-A is promoted because the amino acid residues forming the interface are a combination of positive and negative charges, the intended association between CH1-B and CL-B is not inhibited because the amino acid residues forming the interface are amino acids that do not electrostatically repel each other. As a result, an antibody having the intended association between CH1-A and CL-A, and the intended association between CH1-B and CL-B can be effectively obtained. Meanwhile, in this example, when the amino acid residues forming the interface between CL-B and CH1-B are not uncharged or nonpolar amino acids in CH1-B, they can be modified to become uncharged or nonpolar amino acids.

[0737] Furthermore, by using the association regulation of the present invention, the association between CH1s (CH1-A and CH1-B) or the association between CLs (CL-A and CL-B) can be suppressed.

[0738] One skilled in the art will be able to appropriately determine the types of amino acid residues that come into proximity during association at the CH1 and CL interface in a desired polypeptide for which it is desired to modulate association via the present invention.

[0739] In addition, those skilled in the art can also appropriately obtain the sequence of CH1 or CL that can be used as an antibody in an organism such as human, monkey, mouse, rabbit, etc. by using a public database, etc. More specifically, the amino acid sequence information of CH1 or CL can be obtained by the means described in the following examples.

[0740] For example, with respect to the bispecific antibodies described in the following examples, specific examples of amino acid residues that are close to (opposite to or in contact with) at the interface of CH1 and CL after association include the combinations shown below:

[0741] - glutamine (Q) at position 175 according to EU numbering in CH1 and the opposite (contacting) threonine (T) or serine (S) at position 180 according to Kabat numbering in CL;

[0742] - glutamine (Q) at position 175 according to EU numbering in CH1 and the opposite (contacting) threonine (T) or serine (S) at position 131 according to Kabat numbering in CL;

[0743] - a glutamine (Q) at position 175 according to EU numbering in CH1, and an opposite (contacting) serine (S) or threonine (T) at position 131 and a serine (S) or threonine (T) at position 180 in CL according to Kabat numbering; and,

[0744] - a lysine (K) at position 147 and a glutamine (Q) at position 175 in CH1 according to EU numbering, and an opposite (contacting) serine (S) or threonine (T) at position 131 and a serine (S) or threonine (T) at position 180 in CL according to Kabat numbering.

[0745] The numbering described in the EU numbering in the present invention is represented according to the EU numbering (Sequences of proteins of immunological interest, NIH Publication No.91-3242). In the present invention, the phrases "amino acid residue at position X according to EU numbering" and "amino acid at position X according to EU numbering" (wherein X is an arbitrary number) can also be read as "amino acid residue corresponding to position X according to EU numbering" and "amino acid corresponding to position X according to EU numbering". As shown in the examples described below, the desired antigen binding molecules can be preferentially obtained by modifying these amino acid residues and implementing the method of the present invention.

[0746] In one embodiment, the present invention provides an antigen-binding molecule in which the association of the heavy chain and the light chain is modulated, wherein one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) to (c) below in the heavy chain and the light chain of the antigen-binding molecule are amino acid residues that electrostatically repel each other:

[0747] (a) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 180 according to Kabat numbering in CL;

[0748] (b) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 131 according to Kabat numbering in CL; and

[0749] (c) the amino acid residues comprised at positions 147 and 175 according to EU numbering in CH1, and the amino acid residues comprised at positions 131 and 180 according to Kabat numbering in CL.

[0750] In the aforementioned antigen-binding molecules, the "amino acid residues that electrically repel each other" or "amino acid residues having the same charge" are preferably selected from, for example, the amino acid residues contained in the group consisting of (X) or (Y) below:

[0751] (X) glutamic acid (E) or aspartic acid (D); or

[0752] (Y) lysine (K), arginine (R) or histidine (H).

[0753] In the aforementioned antigen-binding molecules, specific examples of the group of amino acid residues that electrostatically repel each other include the following groups of amino acid residues:

[0754] (a) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 180 according to EU numbering in CL;

[0755] (b) the amino acid residue at position 175 according to EU numbering in CH1 and the amino acid residue at position 131 according to Kabat numbering in CL;

[0756] (c) the amino acid residues at positions 147 and 175 in CH1 according to EU numbering and the amino acid residues at positions 131 and 180 in CL according to Kabat numbering;

[0757] (d) the amino acid residue comprised at position 175 according to EU numbering in CH1, and the amino acid residues comprised at positions 131 and 180 according to Kabat numbering in CL.

[0758] The present invention provides an antigen-binding molecule, wherein one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a1) to (c2) below in the heavy chain and light chain of the antigen-binding molecule are mutually electrically repelling amino acid residues:

[0759] (a1) an amino acid residue at position 175 according to EU numbering in CH1 that is glutamic acid (E) or aspartic acid (D), and an amino acid residue at position 180 according to EU numbering in CL that is glutamic acid (E) or aspartic acid (D);

[0760] (a2) an amino acid residue at position 175 according to EU numbering in CH1 that is lysine (K), histidine (H) or arginine (R), and an amino acid residue at position 180 according to EU numbering in CL that is lysine (K), histidine (H) or arginine (R);

[0761] (b1) an amino acid residue at position 175 according to EU numbering in CH1 that is glutamic acid (E) or aspartic acid (D), and an amino acid residue at position 131 according to EU numbering in CL that is glutamic acid (E) or aspartic acid (D);

[0762] (b2) an amino acid residue at position 175 according to EU numbering in CH1 that is lysine (K), histidine (H) or arginine (R), and an amino acid residue at position 131 according to EU numbering in CL that is lysine (K), histidine (H) or arginine (R);

[0763] (c1) the amino acid residues contained at positions 147 and 175 according to EU numbering in CH1 are each glutamic acid (E) or aspartic acid (D), and the amino acid residues contained at positions 131 and 180 according to EU numbering in CL are each glutamic acid (E) or aspartic acid (D);

[0764] (c2) the amino acid residues at positions 147 and 175 according to EU numbering in CH1, each of which is lysine (K), histidine (H) or arginine (R), and the amino acid residues at positions 131 and 180 according to EU numbering in CL, each of which is lysine (K), histidine (H) or arginine (R).

[0765] In the aforementioned antigen-binding molecules, specific examples of amino acid residues that electrostatically repel each other include the following amino acid residues:

[0766] (a1) an amino acid residue at position 175 according to EU numbering in CH1 that is glutamic acid (E) or aspartic acid (D), and an amino acid residue at position 180 according to EU numbering in CL that is glutamic acid (E) or aspartic acid (D);

[0767] (a2) an amino acid residue at position 175 according to EU numbering in CH1 that is lysine (K), histidine (H) or arginine (R), and an amino acid residue at position 180 according to EU numbering in CL that is lysine (K), histidine (H) or arginine (R);

[0768] (b1) an amino acid residue at position 175 according to EU numbering in CH1 that is glutamic acid (E) or aspartic acid (D), and an amino acid residue at position 131 according to EU numbering in CL that is glutamic acid (E) or aspartic acid (D);

[0769] (b2) an amino acid residue at position 175 according to EU numbering in CH1 that is lysine (K), histidine (H) or arginine (R), and an amino acid residue at position 131 according to EU numbering in CL that is lysine (K), histidine (H) or arginine (R);

[0770] (c1) the amino acid residues at positions 147 and 175 according to EU numbering in CH1, each of which is glutamic acid (E) or aspartic acid (D), and the amino acid residues at positions 131 and 180 according to EU numbering in CL, each of which is glutamic acid (E) or aspartic acid (D);

[0771] (c2) the amino acid residues contained at positions 147 and 175 according to EU numbering in CH1, each of which is lysine (K), histidine (H) or arginine (R), and the amino acid residues contained at positions 131 and 180 according to EU numbering in CL, each of which is lysine (K), histidine (H) or arginine (R);

[0772] (d1) an amino acid residue at position 175 according to EU numbering in CH1 that is glutamic acid (E) or aspartic acid (D), and an amino acid residue at positions 131 and 180 according to EU numbering in CL that is each glutamic acid (E) or aspartic acid (D);

[0773] (d2) the amino acid residue at position 175 according to EU numbering in CH1 is lysine (K), histidine (H) or arginine (R), and the amino acid residues at positions 131 and 180 according to EU numbering in CL are each lysine (K), histidine (H) or arginine (R).

[0774] In addition to the above, the technology of suppressing non-target CH1 / CL association by introducing charge repulsion at the interface between CH1 and CL (WO 2013 / 065708) can be further applied to the antigen-binding molecules of the present invention. More specifically, the present invention provides an antigen-binding molecule having CH1 and CL, wherein one or two or more groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) to (d) below electrically repel each other:

[0775] (a) the amino acid residue contained at position 147 according to EU numbering in the heavy chain constant region (CH1), and the amino acid residue contained at position 180 according to EU numbering in the light chain constant region (CL);

[0776] (b) the amino acid residue contained at position 147 according to EU numbering in CH1 and the amino acid residue contained at position 131 according to EU numbering in CL;

[0777] (c) the amino acid residue contained at position 175 according to EU numbering in CH1 and the amino acid residue contained at position 160 according to EU numbering in CL;

[0778] (d) the amino acid residue contained at position 213 according to EU numbering in CH1, and the amino acid residue contained at position 123 according to EU numbering in CL.

[0779] The technology of introducing electric repulsion into the interface of the second constant region (CH2) of the heavy chain or the third constant region (CH3) of the heavy chain to inhibit unwanted association between heavy chains, the technology of introducing electric repulsion into the interface of the heavy chain variable region and the light chain variable region to inhibit unwanted association between the heavy chain and the light chain, or the technology of modifying the amino acid residues forming the hydrophobic core present at the interface of the heavy chain variable region and the light chain variable region into polar amino acids with a charge to inhibit unwanted association between the heavy chain and the light chain can be further applied to the antigen-binding molecules of the present invention (see WO 2006 / 106905).

[0780] In the technique of suppressing undesired association between heavy chains by introducing electric repulsion at the interface of CH2 or CH3, examples of amino acid residues contacting at the interface of other constant regions of heavy chains include regions corresponding to position 356 (EU numbering) and position 439 (EU numbering), position 357 (EU numbering) and position 370 (EU numbering), and position 399 (EU numbering) and position 409 (EU numbering) in the CH3 region. For the numbering of antibody constant regions, reference can be made to the publications of Kabat et al. (Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, NIH); for the numbering of heavy chain constant regions, EU numbering is shown.

[0781] More specifically, for example, in an antigen-binding molecule containing two types of heavy chain CH3 regions, 1 to 3 groups of amino acid residues in the first heavy chain CH3 region (which are selected from the following amino acid residue groups (1) to (3)) can allow mutual electrical repulsion:

[0782] (1) the amino acid residues comprised at positions 356 and 439 according to EU numbering in the heavy chain CH3 region;

[0783] (2) the amino acid residues comprised at positions 357 and 370 according to EU numbering in the heavy chain CH3 region; and

[0784] (3) The amino acid residues contained at positions 399 and 409 according to EU numbering in the heavy chain CH3 region.

[0785] Furthermore, the antibody may be an antibody having a group of amino acid residues in a second heavy chain CH3 region different from the aforementioned first heavy chain CH3 region, wherein the group of amino acid residues is selected from the groups of amino acid residues shown in (1) to (3) above, and wherein 1 to 3 groups of amino acid residues corresponding to the groups of amino acid residues shown in (1) to (3) above, which electrically repel each other in the first heavy chain CH3 region, do not electrically repel the corresponding amino acid residues in the first heavy chain CH3 region.

[0786] The amino acid residues described in (1) to (3) above are close to each other after association. A person skilled in the art will be able to find the sites corresponding to the amino acid residues described in (1) to (3) above for the desired heavy chain CH3 region or heavy chain constant region by homology modeling, etc. using commercially available software, and appropriately modify the amino acid residues at those sites.

[0787] In the aforementioned antigen-binding molecules, “electrically repel” or “have the same charge” means, for example, that any two or more amino acid residues have amino acid residues included in any one of the groups of (X) and (Y) described above.

[0788] In a preferred embodiment of the aforementioned antigen-binding molecule, the first heavy chain CH3 region and the second heavy chain CH3 region can be cross-linked by a disulfide bond.

[0789] In the present invention, the amino acid residues that are "modified" are not limited to the amino acid residues in the variable region of the above-mentioned antigen-binding molecules or the constant region of the antibody. Those skilled in the art will be able to use commercially available software to find the amino acid residues that form the interface in the polypeptide variant or the heteropolymer by homology modeling, etc., and modify the amino acid residues at those sites to regulate the association. Homology modeling is a technique for predicting the three-dimensional structure of a protein using commercially available software. When constructing the structure of a protein with an unknown three-dimensional structure, first search for a protein that has been determined to have a three-dimensional structure that is highly homologous to the protein. Next, use this three-dimensional structure as a template to construct the structure of a protein with an unknown structure, and further optimize the structure by molecular dynamics methods, etc. to predict the three-dimensional structure of an unknown protein.

[0790] In the technique of introducing electric repulsion into the interface of the heavy chain variable region and the light chain variable region to inhibit the undesired association of the heavy chain and the light chain, examples of the amino acid residues in contact at the interface of the heavy chain variable region (VH) and the light chain variable region (VL) include glutamine (Q) at position 39 according to Kabat numbering in VH (FR2 region) and glutamine (Q) opposite (contacting) at position 38 according to Kabat numbering in VL (FR2 region). In addition, preferred examples are leucine (L) at position 45 according to Kabat numbering in VH (FR2) and proline (P) opposite to position 44 according to Kabat numbering in VL (FR2). For the numbering of these sites, it is mentioned in the publication of Kabat et al. (Kabat, EA et al., 1991, Sequence of Proteins of Immunological Interest, NIH).

[0791] Since these amino acid residues are known to be highly conserved between humans and mice (J. Mol. Recognit. 2003; 16: 113-120), the association of the variable regions of the antigen-binding molecules can be regulated by modifying the amino acid residues corresponding to the above-mentioned amino acid residues, for VH-VL association of antigen-binding molecules other than those indicated in the Examples.

[0792] A specific example is an antigen-binding molecule in which two or more amino acid residues forming the interface of VH and VL are amino acid residues that electrically repel each other. More specifically, examples include antigen-binding molecules having one or two groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) or (b) below:

[0793] (a) the amino acid residue at position 39 according to Kabat numbering in VH and the amino acid residue at position 38 according to Kabat numbering in VL; or

[0794] (b) The amino acid residue at position 45 in VH according to Kabat numbering, and the amino acid residue at position 44 in VL according to Kabat numbering.

[0795] Each amino acid residue described in (a) or (b) above is close to each other when associated. Those skilled in the art will be able to find the sites corresponding to the amino acid residues described in (a) or (b) above in the desired VH or VL by homology modeling, etc. using commercially available software, and appropriately modify the amino acid residues at those sites.

[0796] In the aforementioned antigen-binding molecules, the "amino acid residues that electrically repel each other" are preferably selected from, for example, the amino acid residues contained in any one of the following groups (X) and (Y):

[0797] (X) glutamic acid (E) or aspartic acid (D); or

[0798] (Y) lysine (K), arginine (R) or histidine (H).

[0799] In the technique of modifying the amino acid residues forming the hydrophobic core present at the interface of VH and VL into polar amino acids having a charge in order to suppress the undesired association of the heavy chain and the light chain, preferred examples of the amino acid residues capable of forming the hydrophobic core at the interface of VH and VL include leucine (L) at position 45 according to Kabat numbering in VH (FR2) and opposite proline (P) at position 44 according to Kabat numbering in VL (FR2). For the numbering of these sites, Kabat et al. (Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, NIH) is used as a reference.

[0800] Generally, the term "hydrophobic core" refers to the part assembled by the hydrophobic amino acid side chains inside the associated polypeptide. Examples of hydrophobic amino acids include alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine. In addition, amino acid residues other than hydrophobic amino acids (such as tyrosine) may be involved in the formation of the hydrophobic core. The hydrophobic core, together with the hydrophilic surface (wherein the hydrophilic amino acid side chains are exposed to the outside), becomes a driving force to promote the association of water-soluble polypeptides. When the hydrophobic amino acids of two different domains are present on the molecular surface and exposed to water molecules, entropy will increase, and free energy will increase. Therefore, the two domains will associate with each other to reduce free energy and become stable, and the hydrophobic amino acids at the interface will be buried inside the molecule to form a hydrophobic core.

[0801] It is thought that when polypeptide association occurs, the formation of the hydrophobic core can be suppressed by modifying the hydrophobic amino acids that form the hydrophobic core to polar amino acids having a charge; therefore, it is thought that polypeptide association is suppressed.

[0802] By analyzing the amino acid sequence of the desired antigen binding molecule, those skilled in the art will be able to identify the presence or absence of the hydrophobic core, the formation site (region) etc. That is, the antigen binding molecule of the present invention is characterized in that the amino acid residues that can form the hydrophobic core at the interface are modified into the antigen binding molecule of the amino acid residues with charge. More specifically, examples include antigen binding molecules, wherein the amino acid residues shown in any one of the following (1) or (2) are amino acid residues with charge. The side chains of the amino acid residues shown in the following (1) and (2) are adjacent to each other, and the hydrophobic core can be formed:

[0803] (1) the amino acid residue at position 45 according to Kabat numbering comprised in VH; and

[0804] (2) The amino acid residue at position 44 according to Kabat numbering comprised in VL.

[0805] Preferred examples of the charged amino acid residues in the aforementioned antigen-binding molecules include glutamic acid (E), aspartic acid (D), lysine (K), arginine (R) and histidine (H). More preferred examples include glutamic acid (E) and lysine (K).

[0806] Generally, the amino acid residues described in (1) and (2) above in humans and mice are:

[0807] (1) leucine (L), and

[0808] (2) Proline (P).

[0809] Therefore, in a preferred embodiment of the present invention, these amino acid residues are modified (such as substituted with charged amino acids). In addition, the types of the aforementioned amino acid residues in (1) and (2) are not necessarily limited to the aforementioned amino acid residues, but may also be other amino acids equivalent to these amino acid residues.

[0810] Other known techniques can be applied to the antigen binding molecules of the present invention. For example, in order to promote the association of the first VH (VH1) and the first VL (VL1) and / or the second VH (VH2) and the second VL (VL2), the amino acid side chains present in the variable region of one H chain can be replaced by larger side chains (knobs), and the amino acid side chains present in the relative variable region of the other H chain can be replaced by smaller side chains (holes), so that the knobs can be configured in the holes, and promote the association of VH1 and VL1 and / or VH2 and VL2; As a result, the association of VH1...

Claims

1. A bispecific antibody comprising a first antibody heavy chain and a first antibody light chain that bind to coagulation factor IX and / or activated coagulation factor IX, and a second antibody heavy chain and a second antibody light chain that bind to coagulation factor X, wherein the bispecific antibody is any one of the following (a) to (t): (a) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 61, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 84; (b) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 73, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 84; (c) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 63, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; (d) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 58, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 64, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; (e) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 75, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; (f) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 76, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 87; (g) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 62, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; (h) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 65, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; (i) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 74, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 85; (j) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 66, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; (k) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; (l) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 67, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 89; (m) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; (n) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 68, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 78, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 89; (o) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 90; (p) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 59, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 70, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 80, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 91; (q) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 90; (r) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 71, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 81, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 92; (s) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 69, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 82, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 93; (t) a bispecific antibody comprising a first antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 105, a first antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 72, a second antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83, and a second antibody light chain variable region comprising the amino acid sequence of SEQ ID NO:

94.

2. A bispecific antibody comprising a first antibody heavy chain and a first antibody light chain that bind to coagulation factor IX and / or activated coagulation factor IX, and a second antibody heavy chain and a second antibody light chain that bind to coagulation factor X, wherein the bispecific antibody is any one of the following (a) to (v): (a) a bispecific antibody (QH01 / QL21 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 120, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 126, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149; (b) a bispecific antibody (QH02 / QL22 / / JH01 / JL01) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 138, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 149; (c) a bispecific antibody (QH03 / QL23 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 128, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150; (d) a bispecific antibody (QH03 / QL24 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 122, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 129, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150; (e) a bispecific antibody (QH02 / QL22 / / JH03 / JL03) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 140, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 151; (f) a bispecific antibody (QH02 / QL22 / / JH04 / JL04) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 141, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 152; (g) a bispecific antibody (QH02 / QL22 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 121, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 127, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150; (h) a bispecific antibody (QH04 / QL25 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 130, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150; (i) a bispecific antibody (QH04 / QL26 / / JH02 / JL02) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 139, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 150; (j) a bispecific antibody (QH04 / QL26 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 131, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153; (k) a bispecific antibody (QH04 / QL28 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153; (l) a bispecific antibody (QH04 / QL28 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 132, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154; (m) a bispecific antibody (QH04 / QL29 / / JH05 / JL05) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 142, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 153; (n) a bispecific antibody (QH04 / QL29 / / JH06 / JL06) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 133, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 143, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 154; (o) a bispecific antibody (QH06 / QL30 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155; (p) a bispecific antibody (QH04 / QL31 / / JH08 / JL08) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 135, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 145, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 156; (q) a bispecific antibody (QH06 / QL32 / / JH07 / JL07) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155; (r) a bispecific antibody (QH06 / QL32 / / JH09 / JL09) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 146, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 157; (s) a bispecific antibody (QH06 / QL30 / / JH10 / JL10) comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 147, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 158; (t) a bispecific antibody (QH07 / QL33 / / JH11 / JL11), comprising a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 125, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 137, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 148, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO:

159.

3. An isolated nucleic acid encoding the bispecific antibody of claim 1 or 2. A host cell comprising the nucleic acid of claim 3.

5. A method for producing a multispecific antigen-binding molecule, a multispecific antibody, a bispecific antibody or an antigen-binding molecule, wherein the method comprises culturing the host cell of claim 4 to produce the multispecific antigen-binding molecule, the multispecific antibody, the bispecific antibody or the antigen-binding molecule.

6. A pharmaceutical preparation comprising the bispecific antibody according to claim 1 or 2, and a pharmaceutically acceptable carrier.

7. The pharmaceutical preparation according to claim 6, which is used for preventing and / or treating hemophilia A.

8. An antigen-binding molecule whose association between heavy and light chains is regulated, wherein the amino acid residues in the group of amino acid residues shown in the following (A) in the heavy and light chains of the antigen-binding molecule are amino acid residues that electrostatically repel each other: (A) Amino acid residues at positions 147 and 175 according to EU numbering in the heavy chain constant region (CH1), and amino acid residues at positions 131 and 180 according to Kabat numbering in the light chain constant region (CL), provided that the amino acid residue at position 160 according to Kabatt numbering in CL of the antigen-binding molecule has not been modified to be electrically repulsive.

9. A bispecific antibody whose association between heavy chains and light chains is regulated, wherein the bispecific antibody comprises two types of heavy chain constant regions (CH1), CH1-A and CH1-B, and two types of light chain constant regions (CL), CL-A and CL-B, wherein CH1-A associates with CL-A, and CH1-B associates with CL-B, and the amino acid residues shown in (A) below in the CH1-A and CL-B group and the CH1-B and CL-A group of the bispecific antibody are amino acid residues that electrostatically repel each other: (A) Amino acid residues at positions 147 and 175 according to EU numbering in CH1, and amino acid residues at positions 131 and 180 according to Kabat numbering in CL, with the proviso that the amino acid residue at position 160 according to Kabatt numbering in CL of the bispecific antibody is not modified to be electrically repulsive.

10. The antigen-binding molecule of claim 8 or the bispecific antibody of claim 9, wherein the other two or more amino acid residues forming the interface between the heavy chain variable region and the light chain variable region are amino acid residues that electrostatically repel each other.

11. The antigen-binding molecule or bispecific antibody according to claim 10, wherein the amino acid residues that electrostatically repel each other are one or two groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) or (b) below: (a) the amino acid residue at position 39 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 38 according to Kabat numbering in the light chain variable region, (b) the amino acid residue at position 45 according to Kabat numbering in the heavy chain variable region, and the amino acid residue at position 44 according to Kabat numbering in the light chain variable region.

12. The antigen-binding molecule of claim 8 or the bispecific antibody of claim 9, wherein the amino acid residues that electrostatically repel each other are selected from the group consisting of the amino acid residues included in any one of the following (X) or (Y): (X) Glutamic acid (E), Aspartic acid (D), (Y) Lysine (K), Arginine (R), Histidine (H). The antigen-binding molecule of claim 8 , which is a bispecific antibody.

14. A method for producing an antigen-binding molecule whose association between heavy and light chains is modulated, wherein the method comprises the following steps (1) to (3): (1) Modifying the nucleic acids encoding the heavy chain constant region (CH1) and the light chain constant region (CL) so that the amino acid residues selected from the group consisting of the amino acid residues shown in (A) below electrostatically repel each other: (A) the amino acid residues at positions 147 and 175 according to EU numbering in CH1, and the amino acid residues at positions 131 and 180 according to Kabat numbering in CL, with the proviso that the amino acid residue at position 160 according to Kabat numbering in CL is not modified to be electrically repulsive; (2) introducing the modified nucleic acid into a host cell, and culturing the host cell so that the nucleic acid is expressed; (3) Collecting the antigen-binding molecules from the culture of the host cells.

15. A method for regulating the association between heavy chains and light chains in an antigen-binding molecule, wherein the method comprises modifying a nucleic acid so that the amino acid residues in the group of amino acid residues shown in (A) below are amino acid residues that electrostatically repel each other: (A) Amino acid residues at positions 147 and 175 according to EU numbering in the heavy chain constant region (CH1), and amino acid residues at positions 131 and 180 according to Kabat numbering in the light chain constant region (CL), with the proviso that the amino acid residue at position 160 according to Kabat numbering in CL is not modified to be electrically repulsive.

16. The method of claim 14 or 15, wherein the other two or more amino acid residues forming the interface between the heavy chain variable region and the light chain variable region are amino acid residues that electrostatically repel each other.

17. The method according to claim 16, wherein the amino acid residues that electrostatically repel each other are one or two groups of amino acid residues selected from the group consisting of the groups of amino acid residues shown in (a) or (b) below: (a) the amino acid residue at position 39 according to Kabat numbering in the heavy chain variable region and the amino acid residue at position 38 according to Kabat numbering in the light chain variable region, (b) the amino acid residue at position 45 according to Kabat numbering in the heavy chain variable region, and the amino acid residue at position 44 according to Kabat numbering in the light chain variable region.

18. The method of claim 14 or 15, wherein the amino acid residues that electrostatically repel each other are selected from the amino acid residues included in any one of the following (X) or (Y): (X) Glutamic acid (E), Aspartic acid (D), (Y) Lysine (K), Arginine (R), Histidine (H).

19. The method of claim 14 or 15, which is a bispecific antibody.

20. An isolated nucleic acid encoding the antigen-binding molecule of claim 8 or the bispecific antibody of claim 9.

21. A host cell comprising the nucleic acid of claim 20.

22. A method for producing a bispecific antibody or antigen-binding molecule, wherein the method comprises culturing the host cell of claim 21, such that the bispecific antibody or antigen-binding molecule is produced.

23. A pharmaceutical preparation comprising the antigen-binding molecule of claim 8 or the bispecific antibody of claim 9, and a pharmaceutically acceptable carrier.